Proteolysis of CX3CL1 Impacts CX3CR1 Signaling and Therapeutic Benefits in a Tauopathy Model by Finneran, Dylan John
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
November 2018
Proteolysis of CX3CL1 Impacts CX3CR1
Signaling and Therapeutic Benefits in a Tauopathy
Model
Dylan John Finneran
University of South Florida, finnerad@gmail.com
Follow this and additional works at: https://scholarcommons.usf.edu/etd
Part of the Neurosciences Commons
This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.
Scholar Commons Citation
Finneran, Dylan John, "Proteolysis of CX3CL1 Impacts CX3CR1 Signaling and Therapeutic Benefits in a Tauopathy Model" (2018).
Graduate Theses and Dissertations.
https://scholarcommons.usf.edu/etd/7504
  
 
 
 
 
 
Proteolysis of CX3CL1 Impacts CX3CR1 Signaling and Therapeutic Benefits in a 
 
Tauopathy Model 
 
 
 
by 
 
 
 
Dylan J. Finneran 
 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy in Medical Science 
with a concentration in Neuroscience 
Department of Molecular Pharmacology & Physiology 
College of Medicine 
University of South Florida 
 
 
Major Professor: Kevin Nash, Ph.D. 
Co-Major Professor: David Morgan, Ph.D. 
Paula Bickford, Ph.D. 
Daniel Lee, Ph.D. 
Edwin Weeber, Ph.D. 
 
 
Date of Approval: 
November 15, 2018 
 
 
 
Keywords: Alzheimer’s disease, neuroinflammation, neurodegeneration, Fractalkine, 
microglia 
 
Copyright © 2018, Dylan J. Finneran 
  
  
 
 
 
 
 
DEDICATION 
 
 Thank you to my family for supporting me throughout my education and allowing 
me the opportunity to pursue my passion. Thank you to my teachers who, at all levels, 
have helped spark my interest in science and research. Thank you to my mentors, who 
have patiently guided me through the ups and downs of my graduate training. 
  
  
 
 
 
 
 
ACKNOWLEDGMENTS 
 
 I wish to acknowledge the support staff in the vivarium for keeping our animals 
healthy to the best of their abilities. The undergraduates who have volunteered in the 
lab, some of whom contributed to this work. The technical assistance of Charles 
Szerekes, Ph.D. for his invaluable help with flow cytometry. 
 
 
i 
 
 
 
 
 
TABLE OF CONTENTS 
 
 
List of Figures ................................................................................................................. iv 
 
Abstract .......................................................................................................................... vi 
 
Chapter One: Neuroinflammation, Alzheimer’s disease, and Fractalkine Signaling ........ 1 
 Abstract ................................................................................................................. 1 
 Alzheimer’s Disease ............................................................................................. 2 
 The Neuroinflammation Hypothesis ...................................................................... 4 
 Fractalkine ............................................................................................................ 9 
  Background ................................................................................................ 9 
  CX3CR1 Knock Out Models and Disease ................................................ 11 
  CX3CL1 Gain of Function Studies ........................................................... 15 
  Fractalkine Signaling: Does the Ligand Matter? ....................................... 16 
 Conclusion .......................................................................................................... 18 
 
Chapter Two: CNS-wide Over Expression of Fractalkine Improves Cognitive 
 Functioning in a Tauopathy Model ........................................................................... 20 
  Abstract ............................................................................................................... 20 
  Introduction ......................................................................................................... 21 
  Methods .............................................................................................................. 23 
   Adeno-associated Virus Production ......................................................... 23 
   Transgenic Mice and Breeding ................................................................. 23 
   Surgical Procedures and Tissue Collection .............................................. 24 
   Tissue Homogenization, ELISA, and Western Blotting ............................ 25 
   Behavioral Assessment ............................................................................ 26 
   Immunohistochemistry ............................................................................. 28 
   RNA Isolation and Real-Time PCR .......................................................... 30 
   Statistical Analysis ................................................................................... 30 
  Results ................................................................................................................ 31 
   Intraventricular Injection of AAV4 Increased Soluble FKN ....................... 31 
   Increased Soluble FKN Expression Ameliorated Hyperactivity and 
    Improved Cognition ............................................................................. 33 
   Increased Soluble FKN Signaling did not Reduce Tauopathy .................. 38 
   Increased Soluble FKN Signaling did not Reduce Microglial 
    Markers ............................................................................................... 38 
  Discussion .......................................................................................................... 44 
 
Chapter Three: FKN Over Expression Protects Against Insoluble Tau Deposition 
 
 
ii 
 in Both a Preventative and Interventional Study Design........................................... 52 
  Abstract ............................................................................................................... 52 
  Introduction ......................................................................................................... 53 
  Methods .............................................................................................................. 56 
   Adeno-associated Virus Production ......................................................... 56 
   Transgenic Mice, Breed, and Suppression with Doxycycline ................... 56 
   Surgical Procedure and Tissue Collection................................................ 56 
   Tissue Homogenization, ELISA, and Western Blotting ............................ 58 
   Behavioral Assessment ............................................................................ 59 
   Statistical Analysis ................................................................................... 61 
  Results ................................................................................................................ 63 
   sFKN Over Expression did not Alter Short-Term Recognition 
    Memory ............................................................................................... 63 
   Brief Suppression of P301L Expression Delayed Onset of 
    Significant Cognitive Impairments in rTg4510s ................................... 66 
   sFKN Over Expression Reduces Tau Phosphorylation ............................ 69 
   sFKN Over Expression Elevates Anti-Inflammatory Cytokines ................ 72 
  Discussion .......................................................................................................... 75 
 
Chapter Four: Concentration and Proteolysis of CX3CL1 May Regulate the 
 Microglial Response to CX3CL1 .............................................................................. 81 
  Abstract ............................................................................................................... 81 
  Introduction ......................................................................................................... 82 
  Methods .............................................................................................................. 85 
   Animals .................................................................................................... 85 
   Adeno-associated Virus Production ......................................................... 86 
   Animal Surgery and Tissue Collection ..................................................... 86 
   Tissue Homogenization and Western Blotting .......................................... 87 
   Behavioral Assessment ............................................................................ 88 
   Microglial Isolation .................................................................................... 90 
   Fractalkine Treatments and ELISA .......................................................... 90 
   Flow Cytometry ........................................................................................ 91 
   Beta-Arrestin Screen ................................................................................ 91 
   Statistical Analysis ................................................................................... 92 
  Results ................................................................................................................ 92 
   Different Fractalkine Ligands have Different Receptor Affinities .............. 92 
   High Concentrations of FKN Sensitized Microglia to LPS ........................ 94 
   High Concentrations of hsFKN did not cause CX3CR1 
    Internalization ..................................................................................... 96 
   CX3CR1 Antagonism Exacerbated TNFa Secretion in Primary 
    Microglia ............................................................................................. 96 
   AAV-mediated Over Expression of ckFKN Exacerbated Learning 
    Deficits and Tauopathy in rTg4510 Mice........................................... 100 
  Discussion ........................................................................................................ 104 
 
Chapter Five: Concluding Remarks and Future Directions .......................................... 110 
 
 
iii 
 
References .................................................................................................................. 119 
  
 
 
iv 
 
 
 
 
 
LIST OF FIGURES 
 
 
Figure 1.1: Fractalkine Cleavage Variants ................................................................. 11 
 
Figure 2.1: AAV4 over expressing sFKN transduces ependymal cells leading to 
    increased sFKN in the hippocampus ........................................................ 32 
 
Figure 2.2: AAV4 sFKN over expression reduces hyperactivity and improves 
    social recognition memory........................................................................ 35 
 
Figure 2.3:  Over expression of the ectodomain of FKN does not cause thermal 
    hyperalgesia ............................................................................................. 36 
 
Figure 2.4 sFKN over expression improves performance on RAWM but not on 
    Reversal ................................................................................................... 37 
 
Figure 2.5 sFKN does not ameliorate tauopathy and increases insoluble total 
    tau ............................................................................................................ 39 
 
Figure 2.6 sFKN over expression does not reduce pSer396 phospho-tau or 
    Gallyas-positive tau tangles ..................................................................... 40 
 
Figure 2.7 rTg4510s have reduced hippocampal volume .......................................... 41 
 
Figure 2.8 sFKN over expression does not reduce microglial activation ................... 42 
 
Figure 2.9 sFKN over expression increases Vegfa expression ................................. 43 
 
Figure 3.1 Study design ............................................................................................ 62 
 
Figure 3.2 sFKN over expression does not increase locomotor activity or 
    improve novel object recognition in Study 1 mice .................................... 64 
 
Figure 3.3 sFKN over expression does not increase locomotor activity or 
    improve novel object recognition in Study 2 mice .................................... 65 
 
Figure 3.4 Study 1 Six-month old rTg4510s were not impaired on the RAWM 
    task .......................................................................................................... 67 
 
Figure 3.5 sFKN over expression in Study 2 modestly improves RAWM 
 
 
v 
    performance but not performance on Reversal ........................................ 68 
 
Figure 3.6 sFKN over expression significantly reduced pSer396 phospho-tau 
    in Study 1 ................................................................................................. 70 
 
Figure 3.7 sFKN over expression in Study 2 significantly differentially altered 
    phospho-tau ............................................................................................. 71 
 
Figure 3.8 sFKN over expression altered microglial phenotype in Study 1 ............... 73 
 
Figure 3.9 sFKN over expression altered microglial phenotype in Study 2 ............... 74 
 
Figure 4.1 hsFKN has greater affinity for CX3CR1 than hckFKN .............................. 93 
 
Figure 4.2 High concentrations of FKN increase TNFa secretion ............................. 95 
 
Figure 4.3 High concentration hsFKN does not cause receptor internalization ......... 98 
 
Figure 4.4 Antagonism of CX3CR1 exacerbated secretion of TNFa by primary 
    microglia in the presence of 100 nM FKN ................................................ 99 
 
Figure 4.5 ckFKN over expression induced hyperlocomotion and impaired 
    recognition memory ................................................................................ 101 
 
Figure 4.6 ckFKN Over Expression Worsened Cognitive Performance on 
    Reversal ................................................................................................. 102 
 
Figure 4.7 ckFKN Over Expression Increased Soluble Tau in rTg4510s ................ 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
 
 
 
 
ABSTRACT 
 
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder and the 
most common form of dementia. The hallmark pathologies of AD are extracellular 
aggregates of amyloid-beta, intracellular aggregates of microtubule associated protein 
tau and increased neuroinflammation. Current therapeutics offer only symptomatic relief 
and clinical trials investigating therapeutic benefits of non-steroidal anti-inflammatory 
drugs have yielded no positive results. Therefore, recent work has focused on 
immunomodulators, such as CD200 and fractalkine, as potential therapeutic targets for 
AD.  
Fractalkine (CX3CL1; FKN) is expressed as a transmembrane protein with an N-
terminal chemokine domain followed by a long, mucin-like stalk. FKN can signal as a 
membrane-bound protein or, upon cleavage, as a soluble ligand (sFKN). Upon binding 
its receptor, FKN reduces expression of pro-inflammatory genes in activated microglia. 
Disrupting FKN signaling has been shown to exacerbate neurodegeneration in a 
number or neurodegenerative diseases. Relevant to this study, there have been 
conflicting reports on how FKN signaling affects AD pathology and whether a soluble 
FKN is beneficial or not. Here, we examine the ability of soluble FKN over expression to 
impact tauopathy and the resulting cognitive deficits in the rTg4510 mouse model of 
tauopathy, focusing on cognitive improvement after the onset of tau deposition. 
 
 
vii 
Furthermore, we explore the functional activity of proteolytic fragments of FKN on 
activated microglia in vitro to rectify the contradictory findings in the literature. 
We observed that sFKN over expression can significantly reduce both soluble 
and insoluble phospho-tau in both a preventative and an early interventional study 
design. However, in animals with significant pathology and neurodegeneration we did 
not observe an impact of sFKN over expression on tau pathology. Interestingly, in these 
late stage animals we did observe an improvement in spatial learning and memory as 
well as a reduction in hyperactivity. This suggests that earlier intervention would likely 
be most beneficial in reducing tau pathology but in late stage AD FKN signaling can still 
have benefits on cognition, likely due to reductions in the inflammatory milieu.  
Current publications suggest that different proteolytic fragments of FKN may 
have different functional signaling. Here we demonstrate that the this may be due to 
differences in receptor binding. sFKN (which includes the mucin-like stalk) exhibited a 
lower EC50 than the ckFKN (soluble chemokine domain), which leads to reduced 
functional efficacy of ckFKN at low concentrations. More interestingly, we also observed 
that high concentrations of FKN, regardless of cleavage variant, is ineffective at 
reducing pro-inflammatory activation of microglial and may in fact elicit a 
proinflammatory response. We hypothesize that FKN may signal through an alternative 
receptor at high concentrations, suggesting an as yet unidentified signaling pathway for 
FKN. Furthermore, we show that the ckFKN does not rescue pathology in the rTg4510 
mouse, as sFKN does. These data may clarify conflicts in the literature and 
demonstrate that care must be taken with respect to in vitro and in vivo studies using 
FKN.
 
 
1 
 
 
 
 
 
CHAPTER ONE: 
NEUROINFLAMMATION, ALZHEIMER’S DISEASE, AND FRACTALKINE 
SIGNALING 
 
Abstract 
 Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder and the 
most common form of dementia. The hallmark pathologies of AD are extracellular 
amyloid plaques and intraneuronal tau tangles. As the understanding of AD has 
progressed, it is now hypothesized that AD is an amyloid-initiated tauopathy with 
neuroinflammation serving as the link between amyloid deposition, tau pathology, and 
neurodegeneration. As microglia are the main immune effectors in the central nervous 
system, they have been the focus of attention in studies investigating the 
neuroinflammatory component of AD. Therefore, recent work has focused on 
immunomodulators, which can alter microglial activation without suppressing activity, as 
potential therapeutics for AD. Fractalkine (CX3CL1; FKN), a unique chemokine with a 
one-to-one relationship with its receptor, signals through its cognate receptor (CX3CR1) 
to reduce expression of pro-inflammatory genes in activated microglia. Disrupting FKN 
signaling has opposing effects on the two hallmark pathologies of AD, but over 
expressing a soluble FKN has been shown to reduce tau pathology while not altering 
amyloid pathology. Recently, differential signaling has been reported when comparing 
two cleavage variants of soluble FKN. These differential effects may explain recent 
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studies reporting seemingly conflicting results regarding the effect of FKN over 
expression on AD pathologies. 
 
Alzheimer’s Disease 
 Alzheimer’s disease (AD), a fatal neurodegenerative disorder and the most 
common form of dementia, is characterized by progressive cognitive decline and 
memory loss. Most AD cases are late-onset and sporadic with the greatest risk factor 
for acquiring AD being age. In adults more than 85 years old, the prevalence of AD is 
greater than one in three, which results in a serious financial burden on patients and 
caregivers. Currently, there are no treatments that halt or slow the progression of the 
disease and the pharmacotherapies available to patients only provide symptomatic 
relief that do not address the underlying pathology (Quefurth and LaFerla 2010). 
 The two pathological hallmarks of AD are an accumulation of misfolded proteins: 
extracellular amyloid beta and intracellular microtubule associated protein tau (MAPT; 
tau). These inclusions lead to severe brain atrophy and neurodegeneration in the 
hippocampus and cortex. The current view is that AD is an amyloid-driven tauopathy 
(Akiyama et al. 2000). Amyloid precursor protein (APP) is cleaved in a sequential 
manner first by b-secretase followed by g-secretase, resulting in the generation of 
amyloid-beta (Ab) and its subsequent accumulation. It is believed that this amyloid 
deposition triggers tau hyperphosphorylation and aggregation, which eventually leads to 
neurodegeneration. This is supported by the fact that individuals with Down Syndrome, 
who have a triplication of all or part of chromosome 21 on which the amyloid precursor 
protein encoding gene resides, often develop amyloid plaques and an AD-like 
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phenotype at a young age. Furthermore, all known mutations that cause familial AD 
either increase the production of or alter the aggregation properties of amyloid beta 
(Selkoe 1996). As such, many human trials have focused on clearing amyloid beta 
aggregates or reducing the amyloid burden on the human brain as a potential 
therapeutic (Gallardo and Holtzman 2017). A body of work has studied this approach, 
but it has yet to bear fruit. 
 In humans, it has been observed that tau pathology correlates more closely with 
neurodegeneration and cognitive impairment than amyloid load (Jack et al. 2013). This 
has led to greater focus on tauopathy and its impact on neurodegeneration in AD. 
Animal models have been constructed that recapitulate many aspects of tauopathy in 
AD and have been used to generate data indicating that clearing tau is beneficial. A 
decoupling of neurofibrillary tangle (NFT) formation from cognitive deficits has been 
observed in mouse models and the number of NFTs is far outweighed by 
neurodegeneration in the human disease (Gomez-Isla et al. 1997; Santacruz et al. 
2005; Spires et al. 2006). Specifically, recent work suggests it is an oligomeric species 
of tau that is thought to be the toxic species (Berger et al. 2007; Spires-Jones et al. 
2011). Passive immunization with antibodies specific to oligomeric tau have 
successfully shown a rescue in behavioral deficits without a significant impact on tau 
hyperphosphorylation or neurofibrillary tangle formation (Castillo-Carranza et al. 2014). 
Together with the behavioral improvements in the absence of reduced NFT burden 
seen by Santacruz et al. (2005) in the conditional rTg4510 mouse model, this suggests 
that some other species of tau mediates cognitive deficits. 
 
 
 
4 
The Neuroinflammation Hypothesis 
 As research into AD has progressed, an addendum has been made to the 
amyloid cascade hypothesis, which inserts neuroinflammation as the causal link 
between amyloid deposition, tau pathology, and neurodegeneration (Akiyama et al. 
2000). Support for this link comes from both human tissue and mouse models, in which 
activated microglia have been observed surrounding amyloid (Morgan et al. 2005). 
Using the microglial translocator protein (TSPO) ligand as a marker of microglial 
activation, longitudinal in vivo imaging of prodromal and AD cases have demonstrated 
that microglial activation correlates with amyloid burden (Edison et al. 2018). 
Furthermore, there appears to be an initial increase in microglial activation early in the 
disease that is sustained, even if plaque burden decreases, suggesting chronic 
activation of microglia (Fan et al. 2017). 
Epidemiological studies have found that long-term, high-dose non-steroidal anti-
inflammatory use reduced an individual’s risk for AD (McGeer et al. 2006). However, 
interventional as well as preventative trials have failed to show significant treatment 
effects (Aisen et al. 2000; Thal et al. 2005). The exact involvement of immune activation 
in AD pathogenesis, whether a cause or consequence, is not yet known. However, it 
has been shown that inflammation can drive AD pathogenesis once it has begun. 
Several studies have shown that increasing inflammation in models of amyloid 
deposition are beneficial while increasing inflammation in tauopathy models is 
detrimental (Herber et al. 2007; Lee et al. 2010a; Lee et al. 2010b; Shaftel et al. 2007). 
 In an acute model, Lee et al. (2010a) stimulated microglia by injecting LPS into 
the hippocampus of 4.5-month-old rTg4510 mice, a tauopathy model, and observed 
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significant increases in pre-tangle phospho-tau one week after administration. In a 
chronic model of inflammation, hTau mice lacking the fractalkine receptor (CX3CR1) 
exhibited not only significantly greater pathology but also a significantly earlier onset of 
pathology and cognitive impairments than hTau mice with intact FKN signaling. 
Furthermore, they observed in CX3CR1-deficient mice that systemic administration of 
LPS was sufficient to cause phosphorylation of endogenous tau at the paired helical 
filament-associated sites AT8 and AT180 (Bhaskar et al. 2010). These studies highlight 
the ability of pro-inflammatory activation of microglia to exacerbate, and even initiate, 
tau pathology. 
Recently, genetic risk-factors for AD have been identified that are expressed 
uniquely in the innate immune system, implicating microglial involvement in AD 
susceptibility and/or pathogenesis (Hollingworth et al. 2011; Jonsson et al. 2013; 
Lambert et al. 2009; Naj et al. 2011; Zhang et al. 2013). Elevations in adaptive and 
innate immune markers have been widely reported in AD – in both animal models and 
human subjects – and correlate with disease progression (reviewed in (Ardura-Fabregat 
et al. 2017; Hopperton et al. 2017)). Polymorphism associations of IL-1 and TNF-a have 
been observed in AD patients (Culpan et al. 2003; Nicoll et al. 2000). Genome-wide 
association studies have identified more than 20 gene variants associated with an 
increased risk of late onset AD (LOAD), including CR1, CD33, MS4A, CLU, and HLA-
DRB5 (reviewed in (Dansokho and Heneka 2017; Villegas-Llerena et al. 2016)). ApoE4 
and, more recently, TREM2, were identified as conferring an increased risk of LOAD 
(Sims et al. 2017). It has been proposed that overproduction of ApoE by activated glia 
might exacerbate inflammation, as ApoE4 stimulated IL-1 at significantly lower 
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concentrations than ApoE3 (Guo et al. 2004). The discovery of these innate immunity 
genes as risk factors for AD further strengthens the link between immune activation and 
Alzheimer’s disease pathogenesis. 
Complement is an innate-immune proteolytic cascade, which can be activated by 
amyloid beta fibrils. Complement proteins can be found colocalized with amyloid beta 
plaques and neurofibrillary tangles in AD brain. Furthermore, the end product of 
complement activation, the membrane attack complex, can be found on neurons in AD 
brain (Akiyama et al. 2000). Binding of the complement proteins C3b to CR1, expressed 
on microglia and myeloid cells, can stimulate phagocytosis. In the context of AD, 
complement cascade triggered by amyloid beta could trigger phagocytosis of amyloid 
beta plaques by CR1 signaling on microglia (Khera and Das 2009). In a mouse model of 
amyloid deposition, inhibition of C3 convertase caused significant increases in amyloid 
deposition (Wyss-Coray et al. 2002). Conversely, a genetic knockout of Crry (mouse 
ortholog of CR1) significantly increased phospho-tau (Killick et al. 2013). 
ABCA7, ATP-binding cassette transporter A7, is involved in the phagocytosis of 
apoptotic cells as well as Fcg receptor-mediated phagocytosis. Hollingworth et al. (2011) 
found a minor allele associated with AD. While it is not clear whether there is any 
altered function or expression associated with these single nucleotide polymorphisms, it 
has been shown that reducing ABCA7 expression reduces phagocytosis and that 
genetic ablation of ABCA7 is embryonic lethal in mice (Jehle et al. 2006). In human 
tissue, it has been observed that ABCA7 is up-regulated and ABCA7 expression 
correlates with disease pathology, suggesting a role in amyloid beta phagocytosis and 
microglial activation (Zhao et al. 2015). 
 
 
7 
Triggering receptor expressed on myeloid cells 2 (TREM2) variants were 
identified as being associated with AD, conferring an increased risk for AD 
approximately equal to carrying one allele of APOE4 (Guerreiro et al. 2013; Jonsson et 
al. 2013). These TREM2 alleles also increase the risk for other neurodegenerative 
diseases such as Parkinson’s disease, amyotrophic lateral sclerosis, and frontotemporal 
dementia. Many of these disease-associated TREM2 alleles are coding variants that 
disrupt TREM2 signaling, whether by producing an inactive protein or reducing affinity 
for down-stream adaptor proteins necessary for signal transduction (Jay et al. 2017b). 
Knocking out TREM2 in models of amyloid deposition had a disease progression-
dependent effect. Early in disease progression, TREM2 knockout mice had reduce 
amyloid beta while disrupting TREM2 later in the disease course resulted in increased 
amyloid beta pathology (Jay et al. 2017a). There is also evidence that knocking out 
TREM2 significantly exacerbates tau pathology in mice (Bemiller et al. 2017). The 
disease-associated R47H allele appears to confer a loss-of-function phenotype, 
although this may be a mouse-specific phenomenon due to activation of a cryptic splice 
site that does not occur in humans (Cheng-Hathaway et al. 2018; Xiang et al. 2018). 
Taken together, these data implicate TREM2 in AD pathogenesis. It may be that 
TREM2 loss-of-function is protective early in AD but becomes detrimental to both 
amyloid and tau pathology as the disease progresses. 
CD33 is a member of the sialic acid-binding immunoglobulin-like lectins 
(SIGLEC), which recognize sialic acid moieties on glycoproteins and glycolipids. 
Signaling through SIGLECs mediates cell adhesion and inhibition of cellular activity. It 
has been shown that antagonizing the receptor with an antibody induces the expression 
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of pro-inflammatory cytokines (Lajaunias et al. 2005). In human AD brain CD33 
expression, as well as the CD33/Iba-1 ratio, is increased, indicating both an increase in 
CD33 as well as an increase in CD33 expression per microglia (Griciuc et al. 2013). 
Furthermore, a CD33 allele associated with reduced risk for AD yielded a reduction in 
CD33 expression and a reduction in insoluble amyloid beta-42. Similarly, knocking out 
CD33 in the APP/PS1 model of amyloidopathy reduced amyloid burden (Griciuc et al. 
2013). However, Bradshaw et al. (2013) reported a reduction in phagocytosis in human 
circulating monocytes carrying the AD-associated CD33 allele. More research is needed 
to better define the role of CD33 signaling in AD pathogenesis. 
The identification of immune-related gene risk factors for AD further implicates 
involvement of the immune system in disease etiology. It may be the case that immune 
activation and inflammation play a dual role in AD, depending on the stage of the 
disease. Of the risk-associated genes discussed, all have been studied in the context of 
amyloid deposition and have shown that a reduction in phagocytic capacity is 
associated with increased amyloid burden. However, both TREM2 and CR1 have 
opposing effects on amyloid and tau pathology, in keeping with the body of work 
indicating that activation of microglia is beneficial for amyloid pathology while 
detrimental to tau pathology. However, microglial dysfunction may also play a role in 
disease progression. 
 There is evidence that microglial function is impaired in age and AD. Hickman et 
al. (2008) observed reduced gene expression of amyloid beta-binding proteins, as well 
as reduced expression of amyloid-degrading enzymes. Furthermore, stimulation of a 
microglial cell line, with tumor necrosis factor (TNF) a recapitulated this phenotype, 
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suggesting that sustained exposure to pro-inflammatory cytokines may inhibit microglial 
function. Recently, beclin 1 was implicated as a regulator of phagocytosis and was 
found to be impaired in human microglia isolated from late-stage AD cases (Lucin et al. 
2013). Given the involvement of microglia in maintenance of CNS homeostasis and 
learning and memory, restoration of normal microglial function by modulating the 
inflammatory milieu may be a potential therapeutic target for AD (Parkhurst et al. 2013). 
The neuroinflammatory hypothesis, that links amyloid deposition to tau pathology 
via immune activation, has support from human tissue, mouse models, and genetic risk 
factors for AD. It appears as though microglia become activated initially and may clear 
amyloid. However, as the disease progresses the ability of microglia to phagocytose 
amyloid reduces and this once protective immune activation turns neurotoxic, directly 
causing neurodegeneration and either leading to or exacerbating tau pathology. Since 
the failure of clinical trials using non-steroidal anti-inflammatory drugs to improve 
cognitive outcomes or reduce conversion to AD, attention has turned to 
immunomodulators as potential therapeutics. These compounds, such as CD200, 
CD22, and CX3CL1 (fractalkine; FKN), modulate, rather than suppress, microglial 
activation. 
 
Fractalkine 
 Background 
Fractalkine (CX3CL1; FKN) is the only member of the CX3C chemokine family 
and, unlike many other chemokines, shares a one-to-one relationship with its cognate 
receptor, CX3CR1 (Bazan et al. 1997; Pan et al. 1997). CX3CR1 is a G-protein coupled 
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receptor (GPCR) that can signal through both the Gq and Gi pathways, in turn activating 
PI-3 kinase pathway (Lyons et al. 2009). Fractalkine is expressed in neurons and 
peripheral endothelial and its receptor is produced by myeloid cells (including microglia), 
T cells, and natural killer cells (Garcia et al. 2013; Hatori et al. 2002). FKN is a type I 
transmembrane protein with an N-terminal chemokine domain attached to a long, highly 
glycosylated mucin-like stalk with a short membrane-spanning domain and intracellular 
domain. FKN can be cleaved by a disintegrin and metalloprotease (ADAM) 10, ADAM 
17, and cathepsin S to generate a soluble fragment (Fig. 1.1) (Clark et al. 2009; Garton 
et al. 2001; Hundhausen et al. 2003). Both the membrane-bound and soluble forms of 
FKN are capable of signaling through CX3CR1, although there may be differences in 
affinity and biological activity between these two ligands (Harrison et al. 1998). 
In the periphery, membrane-bound FKN can promote adhesion of monocytes to 
endothelial cells and the soluble ligand can cause chemotaxis of monocytes, T cells, 
and natural killer cells (Imai et al. 1997; Ostuni et al. 2014). Genetic ablation of FKN 
causes reduced monocyte survival and reduced ability of CX3CR1+ macrophages to 
sense the gut lumen (Kim et al. 2011). Expression of the chemokine domain of FKN 
was sufficient to rescue survival of certain populations of monocytes and to rescue the 
ability of CX3CR1+ macrophages to form transepithelial dendrites. In the CNS, 
fractalkine is predominantly expressed by neurons and CX3CR1 is found only on 
microglia (Cardona et al. 2006; Harrison et al. 1998; Hatori et al. 2002). 
Single nucleotide polymorphisms (SNPs) of CX3CR1 have been implicated as 
risk factors in several diseases. There is a correlation between these two SNPs and 
age-related macular degeneration and coronary artery disease (Chan et al. 2005; Moatti 
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et al. 2001; Nassar et al. 2008; Tuo et al. 2004). These SNPs increase risk for age-
related macular degeneration but reduce the risk of coronary artery disease. It was also 
observed that HIV-positive patients homozygous for both SNPs more rapidly converted 
to AIDs (Faure et al. 2000). These SNPs may impact receptor function, or receptor 
expression on monocytes. There is evidence that these SNPs reduce affinity of the 
receptor for FKN and may reduce surface receptor expression on monocytes (Moatti et 
al. 2001). Genetic knockout of both the receptor and the ligand have shed light on the 
role of FKN signaling in development, homeostasis, and disease. 
 
 
Figure 1.1 Fractalkine Cleavage Variants. 
(A) Full-length FKN variant. (B) Putative ADAM10/17 cleavage variant, generating a 
soluble FKN that includes the mucin-like stalk. (C) A theoretical fragment of FKN 
containing only the chemokine domain. 
 
CX3CR1 Knock Out Models and Disease 
Generation of a reporter mouse, replacing endogenous Cx3cr1 with a GFP 
reporter under control of the Cx3cr1 promoter, demonstrated that CX3CR1 expression 
is restricted to microglia in the CNS (Cardona et al. 2006; Jung et al. 2000). This 
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reporter line has been used extensively to investigate the impacts of disrupting FKN 
signaling from the developing to the aged brain. In development, CX3CR1 deficient 
mice were observed to have delayed synaptic pruning. Microglial number was 
transiently reduced in Cx3cr1-/- mice compared to wild type controls while the number 
of dendritic spines was increased. This indicates that CX3CR1 deficiency may delay 
maturation of synapses by delaying engulfment during development (Paolicelli et al. 
2011). In the adult brain, CX3CR1 has been identified as necessary for layer V cortical 
neuron survival (Ueno et al. 2013). These findings implicated FKN signaling in normal 
brain development and homeostasis but ablation of CX3CR1 also effects cognition. 
Disruption of FKN signaling has deleterious effects on both neurogenesis and 
cognition. Cx3cr1-/- mice were found to have a significant reduction in neurogenesis, 
which could be reversed by IL-1 receptor antagonist administration (Bachstetter et al. 
2011). When behaviorally assessed, these mice were found to have motor learning 
impairments, spatial recall impairments, and fear-associated recall impairments. These 
cognitive impairments were associated with reduced synaptic plasticity. Antagonism of 
IL-1b signaling successfully reversed hippocampal-dependent learning but not motor 
learning (Rogers et al. 2011). 
Disruption of FKN signaling has also been studied in the context of 
neurodegenerative disorders. In a seminal paper, Cardona et al. (2006) described the 
impact of CX3CR1 knock out in several models of neurodegeneration. Broadly, they 
found that microglia lacking CX3CR1 are cytotoxic in models of systemic inflammation, 
amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). Mice lacking 
CX3CR1 were more susceptible to neuron loss upon systemic injection of LPS. 
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Furthermore, adoptive transfer of Cx3cr1-/- microglia from LPS-challenged mice into 
wild-type mice also produced neurotoxicity in the area of the injection site. Interestingly, 
microglia lacking CX3CR1 did not migrate away from the injection site whereas 
microglia with intact CX3CR1 signaling migrated from the injection site. Inhibition of IL-
1b signaling blocked the neurotoxic effects of and restored the migratory capacity of 
Cx3cr1-/- microglia. Similarly, in the SODG93A mouse model of ALS, disruption of FKN 
signaling caused greater neuron loss, reduced hindlimb strength, and shortened 
lifespan. In a toxic model of PD, loss of FKN signaling by knocking out either the 
receptor or the ligand resulted in significantly greater neurotoxicity (Cardona et al. 
2006).  
In models of ischemia the role of FKN has been less straightforward. It has been 
shown that genetic ablation of either CX3CR1 or CX3CL1 reduces infarct size in 
ischemic models (Cipriani et al. 2011; Dénes et al. 2008; Fumagalli et al. 2013; Soriano 
et al. 2002). However, administration of exogenous CX3CL1 into WT rats subjected to 
middle cerebral artery occlusion was found to be beneficial, reducing infarct volume and 
improving behavioral outcomes (Cipriani et al. 2011). These effects were not seen when 
exogenous CX3CL1 was administered to Cx3cl1-/- mice, in which exogenous CX3CL1 
ablated the protective effects observed in untreated Cx3cl1-/- mice. Cipriani et al. (2011) 
attributed these seemingly contradictory results to differential response of wild-type 
primary microglia to exogenous CX3CL1 in vitro. They observed no reduction in TNFa 
secreted from stimulated wild-type microglia after treatment with CX3CL1 whereas 
microglia isolated from Cx3cl1-/- mice did reduce TNFa secretion after treatment with 
CX3CL1. 
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FKN signaling has been studied in spinal cord and brain injury models. In a mild 
TBI model, FKN signaling has been shown to have a temporally-dependent action. In 
the first 15 days after the injury, Cx3cr1-/- mice exhibit significantly less impairment as 
well as reduce pro-inflammatory markers. However, 30 days after injury Cx3cr1-/- mice 
have significantly greater memory impairment on the Morris water maze as well as 
significantly elevated pro-inflammatory markers compared to wild-type controls 
(Febinger et al. 2015). Similar results as those found in stroke models have been 
observed in a spinal cord injury model, that is, disrupting FKN signaling confers 
neuroprotection and improves behavioral outcomes (Donnelly et al. 2011). However, 
these effects were largely attributed to a blunting of the inflammatory phenotype 
acquired by infiltrating monocytes. 
The effects of disrupting FKN agonism has also been studied in AD models. FKN 
expression in both the hippocampus and cortex is reduced in AD brain compared with 
non-demented controls (Cho et al. 2011), suggesting a dysregulation of this pathway in 
AD. Several studies have shed light on the role of FKN signaling in AD. It has been 
shown in two models of amyloid deposition that disrupting FKN signaling by knocking 
out Cx3cr1 is beneficial. In both models, a reduction in amyloid plaques was observed 
accompanied by an increase in microglial phagocytosis (Lee et al. 2010b; Liu et al. 
2010). Conversely, it has been observed that FKN signaling is beneficial in tau 
pathology. In the hTau mouse model of tauopathy, it was observed that disrupting FKN 
signaling worsened pathology and accelerated insoluble tau deposition. These 
increases in pathology were accompanied by an impairment in spatial working memory 
(Bhaskar et al. 2010). A further study showed deficits in Morris Water Maze and, 
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importantly, that CD45 immunoreactivity precedes tau hyperphosphorylation in this 
model. In an adoptive transfer model, wild type mice receiving microglia from hTau 
Cx3cr1-/- mice showed increased AT8 immunoreactivity that could be blocked with IL-
1Ra (Maphis et al. 2015). Additional studies in amyloid models have also observed a 
worsening of tau pathology in the absence of FKN signaling (Cho et al. 2011; Lee et al. 
2014). Thus, FKN may have complex interactions with the hallmark pathologies of AD 
and may be neuroprotective or neurotoxic at different timepoints in disease progression. 
CX3CL1 Gain of Function Studies 
A series of studies have examined the effects of over expression of FKN in 
different neurological disorders. Studies over expressing FKN in PD have found 
increasing CX3CR1 agonism is beneficial. Pabon et al. (2011) described the protective 
effects of a soluble FKN ligand in the 6-hydroxydopamine model of PD. In this model, 
FKN agonism resulted in reduced microglial activation, reduced lesion size, and 
protection of dopaminergic neurons in the substantia nigra. Similar results were 
observed when Cx3cl1-/- mice were lesioned with MPTP and injected with adeno-
associated virus (AAV) over-expressing FKN. Animals injected with FKN showed 
significant improvement compared to AAV over-expressing GFP injected mice (Morganti 
et al. 2012). Finally, increased FKN agonism a viral model of a-synuclein over 
expression has also been found to be protective (Nash et al. 2015).  
Examining the effects of FKN over expression on tauopathy has yielded 
encouraging results. Over expression of a soluble FKN (sFKN; predicted to be the 
ADAM10/17 cleavage product) via adeno-associated virus in the Tg4510 mouse model 
of tauopathy reduced both soluble and insoluble phospho-tau pathology, ameliorated 
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neuron loss, and reduced microglial activation. Interestingly, from the Cx3cr1-/- studies 
described above, one may predict that the FKN over expression may worsen amyloid 
pathology. However, when sFKN was over expressed in the APP/PS1 model of amyloid 
deposition, there was not a significant impact on amyloid pathology (Nash et al. 2013). 
This highlights that CX3CR1 agonism may be a potential target for immunomodulation, 
with beneficial effects on tauopathy and no observed detrimental effects on amyloid 
deposition.  
Fractalkine Signaling: Does the Ligand Matter? 
There is some evidence that different fragments of the FKN ligand may have 
different functional outcomes. Fractalkine signaling has been implicated in neuropathic 
pain in spinal injury models (Clark et al. 2007; Milligan et al. 2004; Sun et al. 2013). In 
these studies, CX3CR1 was antagonized with an antibody, which alleviated the 
neuropathic pain in injury models, or agonized with exogenous fractalkine with 
intrathecal injections in non-injured rats, which induced neuropathic pain. In the latter 
example, these studies used recombinant peptides of FKN that included only the 
chemokine domain and not the mucin-like stalk. Further study identified that cathepsin S 
is necessary for the production of pain-inducing FKN in a spinal injury model (Clark et 
al. 2007; Clark et al. 2009). In silico analysis of substrate preference of cathepsin S 
indicates membrane-bound FKN as a potential substrate (Biniossek et al. 2011; Clark et 
al. 2007; Jones et al. 2013; Ruckrich et al. 2006) and a recent study published that 
cathepsin S cleaves membrane bound FKN to generate a soluble fragment that 
migrates at a lower apparent molecular weight than the ADAM10/17 cleavage product 
(Fonovic et al. 2013). Furthermore, Clark and Malcangio (2012) showed that infusion of 
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a peptide containing just the chemokine domain of FKN (ckFKN) elicits mechanical 
allodynia, while infusion of sFKN (which includes the mucin-like stalk) does not. They 
also demonstrated a difference in calcium mobilization upon binding between these two 
fragments. This strongly suggests that FKN signaling may elicit different effects and/or 
microglial phenotypes depending on the identity of the soluble ligand. 
Indeed, this appears to be the case in neurodegenerative diseases. In 
Parkinson’s disease, several studies have shown that a soluble FKN is necessary for 
neuroprotection in both a MPTP and an a-synuclein over expression model, whereas a 
membrane bound form of FKN had no protective effects (Morganti et al. 2012; Nash et 
al. 2015). The results in Alzheimer’s disease are not as clear. Lee et al. (2014) 
generated APP/PS1 mice that only express the chemokine domain of FKN (ckFKN) and 
observed that this failed to have an impact on either amyloid or tau pathology as 
compared to APP/PS1;Cx3cl1-/- mice. They argued that it is the membrane-bound 
variant of FKN, and not a soluble ligand, that impacts amyloid pathology. In a recent 
report, Bemiller et al. (2018) observed an increased susceptibility to LPS-induced 
tauopathy and microglial activation in mice expressing only ckFKN. Furthermore, hTau 
mice expressing ckFKN had similar phospho-tau pathology and cognitive deficits as 
hTau;Cx3cl1-/- mice, both of which had significantly greater phospho-tau pathology and 
cognitive deficits than hTau mice expressing endogenous FKN. The authors observed a 
reduction in CX3CR1 receptor expression on microglia in ckFKN expressing mice as 
compared to either non-transgenic or Cx3cl1-/- mice, perhaps explaining the reduced 
biological activity of ckFKN as compared to endogenous FKN in this model. Contrary to 
these data, Nash et al. (2013) observed neuroprotective effects using a different soluble 
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FKN, the putative ADAM10/17 cleavage product, which contains the mucin-like stalk 
with the chemokine domain. They observed reductions in atrophy, pathology and 
neurodegeneration (Nash et al. 2013). It may be that the form of the soluble fragment 
(with or without the mucin stalk) affects how the chemokine signals and that proteolytic 
cleavage could be a mechanism for regulation of fractalkine activity in vivo. More 
research is needed to determine if there are differential effects of these soluble FKN 
variants and how this could regulate neuroinflammation. 
 
Conclusion 
Recent discovery of innate immunity genes conferring increased risk of AD has 
sparked greater interest in the role of inflammation in AD. As our understanding of the 
role inflammation plays in AD increases, it becomes increasingly clear that 
immunomodulators are a more attractive therapeutic approach than broadly 
suppressing immune activity. One such target is fractalkine, which shares a one-to-one 
relationship with its receptor. In the CNS, fractalkine is expressed by neurons and 
signals its receptor by microglia, thus allowing neurons to directly influence 
neuroinflammation. Fractalkine’s involvement in neurodegeneration has been relatively 
controversial, with disruption of fractalkine signaling being beneficial in some disease 
states (amyloid pathology and stroke) and yet detrimental in other neurodegenerative 
diseases (PD, ALS and tauopathies). Increasing FKN agonism has been shown to be 
neuroprotective in both AD and PD models, however, there is some controversy in the 
field regarding which form of FKN mediates the observed neuroprotection. More 
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research is needed to fully understand the therapeutic potential of FKN in AD, with 
special attention to ligand processing and how this regulates microglial activation. 
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CHAPTER TWO: 
CNS-WIDE OVER EXPRESSION OF FRACTALKINE IMPROVES COGNITIVE 
FUNCTIONING IN A TAUOPATHY MODEL1 
 
Abstract 
 Accumulating evidence increasingly implicates regulation of neuroinflammation 
as a potential therapeutic target in Alzheimer’s disease and other neurodegenerative 
disorders. Fractalkine (FKN) is a unique chemokine that is expressed and secreted by 
neurons and reduces expression of pro-inflammatory genes. To further demonstrate the 
utility of agents that increase FKN signaling throughout the central nervous system as 
possible therapies for AD, we assessed the impact of soluble FKN (sFKN) over 
expression on cognition in tau depositing rTg450 mice after the onset of cognitive 
deficits. Using adeno-associated virus serotype 4, we infected cells lining the ventricular 
system with soluble FKN to increase FKN signaling over a larger fraction of the brain 
than achieved with intraparenchymal injections. We found that soluble FKN over 
expression by cells lining the ventricles significantly improved cognitive performance on 
social recognition memory and radial arm water maze. These benefits were achieved 
without detectable reductions in tau hyperphosphorylation, hippocampal atrophy, or 
microglial CD45 expression. Utilizing qPCR, we report a significant increase in Vegfa 
                                                        
1 Portions of this chapter have been previously published in Finneran, DJ et al. (2018) and have been reproduced 
with permission from Springer. 
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expression, indicating an increase in trophic support and possible neovascularization in 
AAV-sFKN-injected mice. To our knowledge, this is the first demonstration that FKN 
over expression can rescue cognitive function in a tau depositing mouse line. 
 
Introduction 
 Fractalkine (CX3CL1; FKN) is unique among chemokines because it is the only 
member of the CX3C motif family and has a one-to-one relationship with its receptor, 
CX3CR1 (Bazan et al. 1997; Imai et al. 1997; Pan et al. 1997). Produced as a 
transmembrane protein, FKN can undergo proteolytic cleavage by a disintegrin and 
metalloprotease (ADAM) 10/17 or cathepsin S to produce a secreted, soluble form of 
the protein (sFKN) (Garton et al. 2001; Hundhausen et al. 2003; Jones et al. 2013). 
There is evidence that the membrane-associated (full-length) and ectodomain (soluble) 
forms of FKN may have different functional roles and activate the receptor differently 
(Clark and Malcangio 2012; Kim et al. 2011). In the periphery, the full-length form is 
important for monocyte adhesion to endothelial cells while the soluble form may act as a 
chemoattractant for lymphocytes and monocytes (Imai et al. 1997). In the central 
nervous system (CNS), FKN is produced by neurons and its receptor is expressed only 
on microglia (Cardona et al. 2006; Harrison et al. 1998). FKN signaling in the CNS 
blunts microglial activation, reducing production of pro-inflammatory cytokines such as 
interleukin (IL)-1b, IL-6 and tumor necrosis factor-a (Lyons et al. 2009). 
 Fractalkine’s role in neurodegenerative diseases has been of considerable 
interest in the last few years. Initial work disrupting FKN signaling in animal models 
(receptor or ligand knockouts) demonstrated increased Parkinson’s disease pathology, 
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tauopathy, and amyotrophic lateral sclerosis (Bhaskar et al. 2010; Cardona et al. 2006), 
suggesting that dysregulation of microglial activation can result in worsening of disease 
pathology and neurodegeneration. However, disrupting FKN signaling in amyloid-
depositing mice showed amelioration of the pathology due to increased microglial 
phagocytosis of the extracellular amyloid plaques (Lee et al. 2010b). Conversely, 
studies investigating the over expression of FKN showed opposite results to disruptions 
in signaling, generally leading to favorable improvements in disease pathology. The 
soluble form of FKN was shown to be beneficial in multiple models of Parkinson’s 
disease (Morganti et al. 2012; Nash et al. 2015; Pabon et al. 2011). In Alzheimer’s 
disease, we reported that adeno-associated virus (AAV) over expression of sFKN in the 
hippocampus of the rTg4510 mouse model of tauopathy resulted in reduced tau 
pathology, amelioration of neuron loss, and reduction of microgliosis. However, there 
was no improvement in cognitive performance after sFKN over expression, which may 
be attributed to the limited distribution of the treatment which was targeted to the 
dentate gyrus of the hippocampus (Nash et al. 2013). 
 Here, we further investigate the therapeutic ability of sFKN by addressing two 
questions: does a more global distribution of CNS sFKN expression have a greater 
cognitive impact and can increased sFKN expression have an impact in animals that 
already have advanced tau pathology? The latter would be more clinically informative 
because most AD patients would have significant tau pathology at the time of their 
diagnosis. To achieve this, we used a novel delivery method into five-month old 
rTg4510 animals, which present with insoluble tau and cognitive deficits (Dickey et al. 
2009; Santacruz et al. 2005). We utilized the unique capability of AAV serotype 4 to 
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infect cells lining the ventricular system, combined with the soluble nature of our 
therapeutic gene product, to distribute sFKN to the CNS via secretion into the CSF. This 
has been achieved with other secreted proteins (Davidson et al. 2000a; Liu et al. 2005; 
Tenenbaum et al. 2004). We demonstrate here that elevated sFKN expression via 
AAV4, during late stage disease pathology, can partially rescue behavioral deficits but 
does not appear to alter disease progression.  
 
Methods 
 Adeno-associated Virus Production 
 The ectodomain (amino acids 1 – 336 containing the chemokine domain and 
mucin-like stalk) of mouse fractalkine was isolated from mouse cDNA and cloned into 
pTR2-MCS vector at the Age I and Nhe I sites as described previously (Morganti et al. 
2012; Nash et al. 2013). This vector contained the AAV2 terminal repeats and hybrid 
cytomegalovirus-chicken b-actin (CBA) promoter. A C-terminal hemagglutinin (HA)-tag 
was added for protein detection. rAAV4 particles were generated as described 
previously (Carty et al. 2010) and quantified using a dot-blot method with a non-
radioactive biotinylated probe for fractalkine generated by polymerase chain reaction 
(Burger and Nash 2016; Nash et al. 2013).  
 Transgenic Mice and Breeding 
 Animal experiments were conducted in accordance with the National Institute of 
Health Guide and Use of Laboratory Animals and were approved by the Institutional 
Animal Care and Use committee of the University of South Florida. Parental mutant tau 
and tetracycline-controlled transactivator protein strains were maintained separately and 
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bred to produce rTg4510s and littermate nontransgenic (NonTg) and tetracycline-
controlled transactivator protein (tTA) mice as previously described (Santacruz et al. 
2005). Littermate tTA and NonTg mice were used as behavioral controls, as we 
observed modest differences in performance between tTA and NonTg mice. Study 
animals were given food and water ad libitum and maintained on a 12-hour light/dark 
cycle.  
 Surgical Procedure and Tissue Collection 
 Immediately before surgery, mice were weighed and anesthetized with 
isoflurane. Surgeries were performed using a stereotaxic apparatus using convection 
enhanced delivery as described previously (Burger and Nash 2016; Carty et al. 2010; 
Nash and Gordon 2016). Animals receiving AAV4 sFKN (3.4x1012 vg/mL) were injected 
bilaterally into the lateral ventricles with 5 µL of virus in sterile PBS per site (coordinates 
from bregma: -0.4 mm anteroposterior, ±1.0 mm lateral, & -2.4 mm vertical). Control 
animals received AAV9 UF11 (5x1012 vg/mL) expressing green fluorescent protein 
(GFP) were injected as described previously (Carty et al. 2010).  
 Three months post-surgery, mice were weighed and overdosed with 
pentobarbital (200mg/kg). CSF was collected as described (Liu and Duff 2008) and 
mice were perfused with 25 mL of 0.9% normal saline. Brains were collected 
immediately after perfusion. The right hemisphere was dissected and frozen on dry ice 
for biochemical analysis. The left hemisphere was immersion fixed in 4% 
paraformaldehyde for 24 hours. The fixed hemisphere was cryoprotected with 
successive incubations in 10%, 20%, and 30% sucrose solutions for 24 hours in each 
solution. Brains were frozen on a cold stage and sectioned horizontally (25 µm thick) on 
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a sliding microtome and sections were stored in PBS with 10mM sodium azide at 4 °C. 
For rTg4510 mice, every twelfth section was 50 µm. 
 Tissue Homogenization, ELISA, and Western Blotting 
 Anterior cortex and hippocampal samples were homogenized in TBS with 
protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO, USA; Cat. No. P8340), 
phosphatase inhibitor cocktails II and III (Sigma Aldrich, St. Louis, MO, USA; Cat. Nos. 
P5726 & P0044, respectively), and Benzonase (Sigma Aldrich, St. Louis, MO, USA; 25 
U/mL final concentration) at 10 vol/wt of tissue. Tissue was homogenized with a rotating 
pestle and briefly sonicated (3 x 3 s). The samples were centrifuged for 10 minutes at 
10,000 x g at 4 °C. An aliquot (15 µL) of the resulting supernatant was taken for FKN 
ELISA. The pellet was resuspended in the remaining supernatant and detergents added 
to a final concentration of 0.01% SDS, 0.1% NP40, and 0.05% sodium deoxycholate. 
Samples were then centrifuged at 40,000 x g for 30 min at 4 °C. The resulting pellet was 
resuspended in 70% formic acid (2 µL/mg tissue) and incubated for 60 min at room 
temperature. An equal volume of 1M Tris pH 7.5 was added and the sample was 
neutralized to pH 7.5 with NaOH if needed. The soluble fraction was taken for Western 
blotting and total protein concentration was determined by Pierce BCA protein assay 
(ThermoFisher Scientific, Walthman, MA, USA). For Western blotting, 1 µg of protein 
was loaded for each sample. H150 (total tau; Sigma), anti-phospho-Ser199/202 tau  
(pSer199/202, Anaspec, Fremont, CA, USA), and anti-phosphoSer396 tau (pSer396, 
Anaspec, Fremont, CA, USA) were used to assess tau pathology. All signals were 
normalized to b-actin (ThermoFisher Scientific, Walthman, MA, USA). For the insoluble 
fraction, which does not contain actin, an equal volume of each sample was loaded. A 
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fractalkine ELISA was obtained from R&D Systems and the manufacturer’s protocol 
was followed. 
 Behavioral Assessment 
 All behavioral tasks were conducted by an observer blinded to treatment 
condition and genotype of the mice. The open field was used as a general measure of 
activity and anxiety. Animals were recorded for 15 minutes in a 40 cm by 40 cm open 
field box with video tracking software (ANY-Maze, Stoelting, Wood Dale, IL, USA). 
General activity levels were evaluated by distance traveled in the open field. 
 Each animal was placed for a single, 5-minute trial in a Y-maze and activity was 
recorded (ANY-Maze, Stoelting, Wood Dale, IL, USA). The number of arm entries and 
spontaneous alternation, entering each arm in sequence without repetition, was 
expressed as a percentage as previously described (Brownlow et al. 2014). 
 Short term memory was evaluated by the novel object recognition task. Two 
objects, similar in scale to the mice, were placed in the 40 cm x 40 cm open field arena 
approximately 3-5 cm from the outer wall. Each animal was given three 5-minute 
familiarization trials with a 5-minute inter-trial interval. On the fourth trial, one of the 
objects was switched for a novel object. Animals were given five minutes to explore the 
objects and their activity was recorded (ANY-Maze, Stoelting, Wood Dale, IL, USA). The 
objects and arena were cleaned between trials with 10% ethanol to minimize olfactory 
cues. Working memory was evaluated by measuring the time spent with familiar object 
and novel object on the final trial. 
 To overcome the disinterest the mice showed in the objects, the mice were also 
tested in a variant of the NOR task using unfamiliar mice as the stimuli as previously 
 
 
27 
described (Brownlow et al. 2014). Briefly, the test mouse was given one 5-minute 
habituation trial to its environment. It was then introduced to two sex-matched bait mice, 
located in the left or right chamber of the three-chambered arena. The test mouse had 
two five-minute trials with a five-minute inter-trial interval to familiarize itself with the bait 
mouse. On the fourth trial, one of the bait mice was switched for a novel bait mouse. 
The test mouse was given another five minutes to explore the arena and its activity was 
recorded (ANY-Maze, Stoelting, Wood Dale, IL, USA). Preference for the novel mouse 
was assessed by measuring time spent in the chamber of the arena containing the 
novel mouse. 
 Radial arm water maze (RAWM) has been described in detail, including sample 
score sheets, previously (Alamed et al. 2006). The radial arm water maze contained six 
arms radiating from an open central area with a hidden escape platform located at the 
end of one of the arms. Around the pool, several extra-maze cues were hung to allow 
for spatial navigation. On each trial, the mouse was allowed 60 seconds to find the 
platform. The platform was located in the same goal arm on each trial. On day one, the 
mice were given 15 trials alternating between a visible and hidden platform. On day two, 
mice were given 15 additional trials, all with a hidden platform. The start arm was varied 
for each trial, forcing mice to rely on the extra-maze spatial cues to find the platform 
instead of procedural memory. The goal arm for each mouse was different to avoid odor 
cues revealing the platform location. Entry into an incorrect arm (all four limbs in the 
arm) was counted as an error. Failure to enter an arm for 15 seconds was also counted 
as an error. The errors of blocks of three trials were averaged for data analysis. Mice 
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that made one or fewer errors on the last block of Day 2 were considered to have 
learned the platform location. 
 On the third day, a reversal trial was performed with the goal arm moved 180° 
across the pool. The mice were again given 15 trials, all with the hidden platform, to 
learn its new location. On the fourth day, the arm insert was removed from the pool, the 
extra-maze cues were taken down, and the platform was raised above the surface of 
the water with a flag attached to confirm that all mice were able to see and capable of 
ascending the platform. Latency to find and ascend the platform was recorded with a 
maximum swim time of 60s. 
 To assess thermal hyperalgesia, mice were placed on a hot plate at 50 °C. 
Latency to hind paw withdrawal was measured (Woolfe and Macdonald 1944). 
 Immunohistochemistry 
 Six to eight sections approximately 200 µm apart spanning the hippocampus 
were chosen for analysis. Immunohistochemical experiments were performed as 
described previously (Gordon et al. 2002). Briefly, sections for each animal were placed 
into a multisample staining tray. Endogenous peroxidases were blocked (10% 
methanol, 3% hydrogen peroxide in PBS for 15min) and tissue was permeabilized 
(0.2% lysine, 0.1% Triton X-100 in PBS for 30min). Sections were incubated overnight 
in appropriate primary antibody: anti-pSer396 (Anaspec, Fremont, CA, USA); anti-CD45 
(ThermoFisher Scientific, Walthman, MA, USA); anti-IBA-1 (Wako, Richmond, VA, 
USA); or HRP-conjugated anti-HA (Roche, Indianapolis, IN, USA). Sections were 
washed three times in PBS, then incubated for two hours with corresponding 
biotinylated secondary antibody (Vector Laboratories, Burlingame, CA, USA), if 
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necessary. The tissue was again washed and incubated with Vectastain Elite ABC Kit 
(Vector Laboratories) for enzyme conjugation. Finally, sections were stained using 
0.05% diaminobenzidine and 0.03% hydrogen peroxide for five minutes. Each 
immunohistochemical assay omitted some sections from primary antibody incubation to 
evaluate nonspecific binding of the secondary. Sections were mounted onto slides, 
dehydrated, and coverslipped. 
 Gallyas staining was performed as previously described (Lee et al. 2010a). 
Staining was performed on pre-mounted tissue sections that had been dried for a 
minimum of 24 hours. Prior to staining sections were rehydrated for 30 seconds. Slides 
were treated with 5% periodic acid for five minutes, washed with water, and incubated 
sequentially in silver iodide (1 minute) and 0.5% acetic acid (10 minutes) prior to being 
placed in developer solution (2.5% sodium carbonate, 0.1% ammonium nitrate, 0.1% 
silver nitrate, 1% tungstosilicic acid, 0.7% formaldehyde). Slides were incubated in 
developer solution until color developed after which they were placed in 0.5% acetic 
acid to stop the reaction (3 minutes). Slides were incubated in 0.1% gold chloride 
solution (5 minutes), washed with water, and incubated in 1% sodium thiosulphate 
solution (5 minutes). After a final wash, slides were dehydrated and coverslipped. 
 Stained sections were imaged using a Zeiss Axioscan.Z1 scanning microscope 
and Neurocyte IAE software (created by Andrew Lesniak) was used for analysis. The 
area of positive staining in the hippocampus was analyzed. The software used hue, 
saturation, and intensity to segment the images and these values were held constant for 
analysis of every section of every animal in each stain. These values were established 
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on sections of high and low levels of staining to identify positive staining over 
background (Gordon et al. 2002). 
 RNA Isolation and Real-Time PCR 
 RNA was isolated from posterior cortex using the Zymo Quick-RNA Miniprep 
Plus kit (Zymo Research, Irvine, CA, USA; cat. no. R1057) per the manufacturer’s 
recommended protocol. EXPRESS One-Step Superscript qRT-PCR Kit (cat. no. 
11718200) and TaqMan Gene Expression Assays were purchased from ThermoFisher 
(Walthman, MA, USA). Primers for the target genes Tnf (Mm00443256_m1), Il1b 
(Mm00434228_m1), Il6 (Mm00446190_m1), Il12a (Mm00434169_m1), Il10 
(Mm01288386_m1), Vegfa (Mm00437306_m1), Il4 (Mm00445259_m1), Marco 
(Mm00440265_m1), Itgam (Mm00434455_m1), CD68 (Mm03047343_m1), Arg1 
(Mm00475988_m1), Nos2 (Mm00440502_m1), C1qa (Mm00432142_m1), Itgax 
(Mm00498701_m1), and the housekeeping gene Pgk1 (Mm00435617_m1) were used 
per the manufacturer’s recommended protocol. Fifty nanograms of RNA were loaded 
per well and data collected in a Bio-Rad CFX96 thermal cycler (50°C for 15 min, 95°C 
for 2 min, 40 cycles of: 95°C for 15 seconds, 60°C for 1 min). Data was analyzed using 
the DDCT method (Schmittgen and Livak 2008). 
 Statistical Analysis 
 Statistical analysis was performed using SPSS Statistics (IBM, Armonk, NY, 
USA). For behavioral tasks, all groups were assessed using a one-way analysis of 
variance (ANOVA) was performed with Fisher’s LSD post-hoc analysis. For the novel 
object recognition task, a two-tailed Student’s t-test was used to compare time spent 
with the familiar object to time spent with the novel object on trial four. The social 
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recognition memory task was analyzed with a two-way ANOVA and Fisher’s LSD with 
Group and Chamber as fixed factors. For tau western blotting and immunostaining, 
where there was no signal from mice lacking P301L tau expression, a two-tailed 
Student’s t-test was utilized to compare sFKN-treated mice to GFP-injected controls. 
Immunostaining for CD45 and IBA-1 was analyzed with a one-way ANOVA and Fisher’s 
LSD post-hoc analysis comparing all groups. The threshold for significance was set at 
p=0.05. 
 
Results 
 Intraventricular Injection of AAV4 Increased Soluble FKN  
 Adeno-associated virus serotype 4 has been reported to readily infect cells lining 
the ventricular system in the CNS (Davidson et al. 2000a; Dodge et al. 2010; Liu et al. 
2005; Tenenbaum et al. 2004). Here, we sought to take advantage of this AAV4 tropism 
to infect cells lining the ventricular system in order to increase the distribution of soluble 
fractalkine (sFKN) agonism throughout the CNS with minimal intracranial injections.  
Fig. 2.1A describes the timing of the FKN administration relative to assessment of 
behavioral, histological and biochemical endpoints. To confirm increased sFKN levels in 
the parenchyma, we performed an ELISA on soluble fractions of brain homogenate 
three months post-injection. Injection with AAV4 sFKN increased sFKN concentrations 
in the hippocampus but not the anterior cortex (Fig. 2.1B) compared with to control-
injected rTg4510s. Staining for anti-HA shows positive staining in the lining of the 
ventricles in injected animals not present in uninjected control mice (Fig. 2.1D). We also 
observed recombinant sFKN expression in the CSF by Western analysis for HA present 
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on the sFKN construct (Fig. 2.1C). Thus, AAV4 over-expressing sFKN delivered into the 
ventricles causes secretion of sFKN into the CSF, which diffuses into the hippocampus 
leading to supraphysiological levels of FKN. 
  
Figure 2.1 AAV4 over expressing sFKN transduces ependymal cells leading to 
increased sFKN in the hippocampus. (A) Study design. Five-month old rTg4510s 
were injected with AAV4-sFKN and survived for two months prior to behavioral 
assessment. Tissue was collected at eight months of age. (B) A FKN ELISA showed 
increased sFKN in the hippocampus of animals injected with AAV4-sFKN compared to 
GFP-injected rTg4510 and uninjected tTA control mice (n=9-12). (C) Anti-HA Western 
blot showed sFKN secretion into the CSF of AAV4-sFKN injected mice. (D) 
Representative images of sections stained for anti-HA showed positive staining in the 
ependyma of animals that received AAV4-sFKN, but not in control mice (scale bar = 
250µm). Data represented as mean ± SEM. * denotes p<0.05 by Fisher’s LSD 
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Increased Soluble FKN Expression Ameliorated Hyperactivity and 
Improved Cognition 
 rTg4510 mice have been shown previously to be hyperactive (Brownlow et al. 
2013; Brownlow et al. 2014; Joly-Amado et al. 2016). We also observed increased 
locomotion in transgenic mice treated with control AAV injections compared with either 
tTA or nontransgenic uninjected mice (Fig. 2.2A & 2.2B). Increased soluble fractalkine 
signaling ameliorated this behavior with sFKN-treated mice both traveling a shorter 
distance in the open field (Fig. 2.2A) and entering fewer arms in the Y-maze (Fig. 2.2B) 
than GFP-injected control mice. We observed no significant differences between groups 
in spontaneous alternation in the Y-maze (data not shown). While sFKN over 
expression did not improve object recognition (Fig. 2.2C), it did significantly improve 
social recognition memory. Mice treated with sFKN spent more time interacting with the 
novel mouse than the familiar mouse while GFP-injected transgenic mice showed no 
preference for either the novel, familiar, or empty center chamber of the apparatus (Fig. 
2.2D). 
 Previous reports have implicated a truncated soluble variant of FKN generated 
by Cathepsin S cleavage in neuropathic pain (Clark and Malcangio 2012; Clark et al. 
2007; Clark et al. 2009). To investigate if the entire ADAM 10/17 cleaved ectodomain of 
FKN may contribute to this, we assessed thermal hyperalgesia on a hot plate. Animals 
over expressing the entire ectodomain of FKN did not have a change in the latency to 
hind paw withdrawal (Fig. 2.3), indicating that they did not have a change in pain 
threshold. Nor did they exhibit any signs of adverse sickness behavior, such as 
 
 
34 
hunching. Thus, we conclude  the mice were not made hyperalgesic by the sFKN 
expression.  
 We have previously reported rTg4510 mice display a deficit in spatial learning 
and memory by five months of age. Using the radial arm water maze task, we observed 
that AAV-GFP-treated control transgenic mice displayed a larger number of errors per 
block compared with either tTA or nontransgenic mice (Fig. 2.4A), commit significantly 
more total errors on both day 1 and day 2 (Fig. 2.4B), and never attain criterion 
performance of <1 error per block by the end of day 2. In contrast, treatment with sFKN 
revealed a partial rescue in performance, with a smaller number of average errors on 
Block 10 and a significant reduction in errors made on Day 2 of testing compared to 
GFP-injected controls (Fig. 2.4A & 2.4B). However, sFKN over expression was not able 
to improve performance in the reversal portion of the task (Fig. 2.4C & 2.4D). Swimming 
and visual performance were assessed using an open pool and visible platform. No 
differences between groups were observed, indicating the deficits observed are due to 
deficiencies in learning and memory (data not shown). 
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Figure 2.2 AAV4 sFKN over expression reduces hyperactivity and improves social 
recognition memory. (A) Distance travelled in open field was reduced in sFKN 
animals; (B) arm entries Y-maze were reduced in sFKN animals. Locomotor activity of 
tTA (hatched bars) and NonTg (open bars) mice was lower than locomotor activity in 
AAV-GFP-injected transgenic mice in both tests. (C) Nontransgenic mice showed a 
preference (increased interaction time) for the novel object over the familiar object in the 
novel object recognition test, but the other test groups showed no preference. (D) 
Nontransgenic, tTA and AAV-sFKN-treated mice showed a significant preference for 
interacting with a novel mouse, but AAV-GFP-treated mice did not. Data represented as 
mean ± SEM, n=9-12. * denotes p<0.05; *** denotes p<0.001 by Fisher’s LSD 
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Figure 2.3 Over expression of the ectodomain of FKN does not cause thermal 
hyperalgesia. Graph of latency to withdraw hind paw from hot plate. Over expression of 
the ectodomain of FKN (with mucin-like stalk), did not affect latency to respond to heat 
after. Data represented as mean ± SEM, n=9-12 
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Figure 2.4 sFKN over expression improves performance on RAWM but not on 
Reversal. (A) Graph of errors made during day 2 training in RAWM. Over expression of 
sFKN reduced average errors made on the last block of day 2; (B) Graph of total errors 
made on day 1 and day 2 of RAWM. sFKN reduced the total number of errors made on 
Day 2 compared to AAV-GFP injected rTg4510s. (C) Errors made during reversal 
testing. (D) Graph of total errors made during reversal testing. sFKN over expression 
did not reduce average errors per block compared GFP animals. Data represented as 
mean ± SEM, n=9-12. * denotes p<0.05; ** denotes p<0.01; *** denotes p<0.001 by 
Fisher’s LSD 
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 Increased Soluble FKN Signaling did not Reduce Tauopathy 
 We did not observe a significant reduction in either total (H150) or phospho-tau 
(pSer199/202 & pSer396) in soluble hippocampal homogenates (Fig. 2.5A & 2.5B) in 
animals treated with sFKN. Unexpectedly, we observed a significant increase in total 
insoluble tau with a trend for increased forms of phospho-tau (Fig. 2.5C & 2.5D). 
However, we did not observe significant increases in immunohistochemical staining of 
pSer396 (Fig. 2.6A & 2.6C) or in Gallyas staining, thought to represent tau tangles (Fig. 
2.6A & 2.6B). Furthermore, we did not observe an amelioration of hippocampal atrophy 
in AAV-sFKN-injected rTg4510s compared to AAV-GFP-injected rTg4510s (Fig. 7). This 
is not unexpected given the mice would have already shown significant atrophy at time 
of viral injection. 
 Increased Soluble FKN Signaling did not Reduce Microglial markers 
 We have previously shown that CD45, a marker of microglial activation, was 
elevated in rTg4510s and that parenchymal sFKN over expression reduced this marker 
(Nash et al. 2013). However, we did not observe a significant reduction in CD45 staining 
in animals over expressing sFKN in this experiment (Fig. 2.8A & 2.8B). Furthermore, we 
did not observe a reduction in IBA-1, a pan-marker for microglia in animals over 
expressing sFKN (Fig. 2.8C). When we examined expression of a panel of innate 
immunity-related genes using RNA from the posterior cortex, we did not observe 
changes in a number of microglial markers but Vegfa was significantly elevated in AAV-
sFKN-injected rTg4510s compared to control injected rTg4510s (Fig. 2.9).  
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Figure 2.5 sFKN does not ameliorate tauopathy and increases insoluble total tau. 
(A) Graph of tau and phospho-tau levels from Western blot analysis. Soluble total tau 
(H150) and phospho-tau (pS199/202 & pS396) were unchanged by sFKN over 
expression. (B) Displays representative Western blots of monomeric tau at 55 kDa. (C) 
Graph of insoluble tau and phospho-tau levels from Western blot analysis. sFKN over 
expression increased insoluble total tau with trends for increased insoluble phospho-
tau. (D) Displays representative Western blot images of monomeric tau at 55 kDa. 
Intensity of blots from all animals were averaged and converted to fold change for 
display. Data represented as mean ± SEM, n=9-12. * denotes p<0.05 by two-tailed 
Student’s t-test 
 
 
40 
 
 
Figure 2.6 sFKN over expression does not reduce pSer396 phospho-tau or 
Gallyas-positive tau tangles. (A) Representative images of hippocampi from mice 
treated with AAV-sFKN, AAV-GFP or control untreated tTA mice after staining by the 
Gallyas method for neurofibrillary tangles (left) or by immunostaining for pSer396 (right). 
Neurons expressing tau are visible in the CA subfield as dark reaction product. Scale 
bar = 200 µm. (B) Percentage area occupied by Gallyas reaction product was quantified 
on 8 sections per mouse, averaged to yield a single value per mouse, then averaged 
over all mice per treatment condition. Although there was a genotype effect with 
rTg4510 mice displaying tangles and tTA mice lacking tangles, there was no effect of 
treatment with sFKN compared with GFP. (C) Similar quantitation of pSer396 phospho-
tau staining as measured by IHC yielded equivalent conclusions. Data represented as 
mean ± SEM, n=9-12. *** denotes p<0.001 by Fisher’s LSD 
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Figure 2.7 rTg4510s have reduced hippocampal volume. Graph of hippocampal 
volume. Hippocampal area was quantified across 8 equally spaced sections spanning 
the hippocampus per mouse, which were averaged to generate one value per animal 
and finally averaged across all mice in one treatment group. rTg4510s have reduced 
hippocampal volume compared to uninjected tTA and NonTg controls. Uninjected tTA 
mice also displayed reduced hippocampal volume compared to uninjected NonTg mice. 
Data represented as mean ± SEM, n=9-12. * denotes p<0.05 by Fisher’s LSD 
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Figure 2.8 sFKN over expression does not reduce microglial activation. (A) 
Representative images of CD45 and IBA-1 immunoreactivity. Scale bar = 20 µm. (B) 
Percentage area staining for CD45. (C) Percentage area staining for IBA-1. 
Immunoreactivity was quantified across 8 sections per mouse, which were averaged to 
generate one value per animal and finally averaged across all mice in one treatment 
group. rTg4510s displayed more area staining of CD45 and IBA-1 than uninjected tTA 
and NonTg controls, but sFKN did not reduce this staining. Data represented as mean ± 
SEM, n=9-12. ** denotes p<0.01, * denotes p<0.05 by Fisher’s LSD 
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Figure 2.9 sFKN over expression increases Vegfa expression. Graph of log base-2 
expression relative to uninjected nontransgenic control mice. Data analyzed using DDCT 
method. Data represented as mean ± SEM, n=4-7. ** denotes p<0.01 by two-tailed 
Student’s t-test 
  
 
 
44 
Discussion 
 Microglia play a key role in Alzheimer’s disease pathogenesis. Previous studies  
showed that increasing microglial activation exacerbates tau pathology while reducing 
microglial activation can reduce tau pathology (Cho et al. 2011; Herber et al. 2007; Lee 
et al. 2010a; Lee et al. 2010b). We previously demonstrated that increasing soluble 
fractalkine agonism in the rTg4510 mouse model of tauopathy reduced pathology and 
neurodegeneration. However, the treatment was administered at a preventative 
timepoint, with administration of virus prior to significant tau pathology formation 
(injection at 3 months of age). In this study we wanted to examine if sFKN could have 
beneficial effects when administered at a more therapeutic timepoint, by administering 
virus after significant disease pathology and memory deficits had already been 
established (injection at 5 months of age). This would reflect a more clinically relevant 
setting where diagnosed patients would already exhibit significant tau deposition and 
cognitive deficits. The current study also differed from our previous work in that our 
delivery method in the previous study targeted only the hippocampus with injections 
directly into the parenchyma; here we sought to maximize treated brain regions while 
minimizing the number of injections required with the use of AAV4. We envisioned that 
intracerebroventricular (ICV) injections would reduce tissue damage to brain regions 
already burdened with pathology, neuron loss, and gliosis while maximizing distribution 
of the therapeutic gene product, another key consideration for translation to the clinic. 
 Previous studies showed the rAAV4 vector can efficiently infect cells of the lateral 
ventricle (Davidson et al. 2000b; Liu et al. 2005). More importantly, it has been reported 
that ICV and intrathecal delivery of AAV4 and AAV2 vectors encoding lysosomal 
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enzymes, which were also secreted from transduced cells, has proven very effective in 
providing therapeutic levels of enzyme throughout the CNS in adult mouse models of 
lysosomal storage disease (Liu et al. 2005; Watson et al. 2006). ICV delivery of an 
AAV4 vector encoding hIFN-β has also been shown to be an effective approach to curb 
glioblastoma tumor growth (Meijer et al. 2009). These data suggest that secretion of 
sFKN from a lateral ventricle injection may be sufficient to provide therapeutic levels of 
sFKN protein throughout the CNS. In this study, we show that AAV4 sFKN infected the 
cells lining the lateral ventricles and increased sFKN levels in the CSF and 
hippocampus of injected mice. We observed sFKN expression in cells throughout the 
ventricular system including the cerebral aqueduct, 3rd and 4th ventricles. Using this 
method, we achieved an approximately 2-fold increase of soluble FKN over 
endogenous levels.  
Previous reports have implicated fractalkine signaling in neuropathic pain in the 
spinal cord (Clark and Malcangio 2012; Milligan et al. 2004). Since we secreted sFKN 
into the CSF, potentially increasing FKN signaling in the spinal cord, we were 
concerned this may have detrimental effects and thus examined the animals for thermal 
hyperalgesia on a hot plate. Animals over expressing sFKN had no change in latency to 
hind paw withdrawal as compared with GFP-injected controls (Fig. 2.3), indicating that 
either the levels of sFKN reaching the spinal cord are insufficient to cause hyperalgesia 
or the species (ADAM 10/17 product) of soluble FKN (aa 1-336) we over expressed 
does not participate in mediating neuropathic pain. The latter would be consistent with 
the data published by Clark and Malcangio (2012). They demonstrated that intrathecal 
administration of a peptide of the chemokine domain (amino acids 1-110 only) results in 
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mechanical hypersensitivity whereas an injection of the sFKN protein does not alter 
sensitivity (Clark and Malcangio 2012). Furthermore, induction of allodynia in spinal 
lesion models has been shown to be mediated, in part, by FKN and requires cathepsin 
S (Clark et al. 2007; Clark et al. 2009). These findings implicate the cathepsin S 
cleavage product of FKN, which migrates at a lower apparent molecular weight by SDS-
PAGE than the ADAM 10/17 cleavage product used in the current study, in the 
induction of neuropathic pain (Fonovic et al. 2013). 
Examining the behavioral phenotype of rTg4510s, we observed FKN expression 
above basal levels ameliorates several behavioral abnormalities. As reported 
previously, rTg4510s are known to be hyperactive and this hyperactivity may be due to 
pathological tau (Joly-Amado et al. 2016). Here, we observed a significant reduction in 
locomotor activity as measured in both the open field and Y-maze (Fig. 2.2). We also 
observed a significant improvement in social recognition memory, however, not novel 
object recognition (Fig. 2.2). This may be due to the greater motivation to interact with 
another mouse as opposed to an inanimate object (Brownlow et al. 2014). In the RAWM 
task, we observed that increased sFKN levels significantly improved hippocampal-
dependent spatial learning and memory (Fig. 2.4). Animals over expressing sFKN made 
significantly fewer errors on Day 2 of the task than GFP-injected rTg4510s. However, 
we observed no improvement in the Reversal task, suggesting that this spatial learning 
improvement was partial. This may be due to the severe pathology that these animals 
already exhibited prior to start of sFKN treatment. This would suggest that earlier 
intervention, prior to significant neuropathology and neurodegeneration, may be a more 
beneficial therapeutic strategy. 
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We believe that the improvements we observed in behavior are due to alterations 
in the inflammatory milieu brought about by sFKN over expression. Previous studies 
have demonstrated that Cx3cr1-/- mice have deficits in cognition and neurogenesis that 
was reversed with IL-1 Receptor Antagonist (IL-1RA) administration (Bachstetter et al. 
2011; Rogers et al. 2011). Microglial-specific cytotoxicity in an adoptive transfer model 
was also blocked by genetic ablation of IL-1 signaling (Cardona et al. 2006). Similarly, 
tau hyperphosphorylation induced by adoptive transfer of activated microglia from LPS-
challenged hTau;Cx3cr1-/- mice into naïve wild-type mice was blocked by 
administration of the IL-1R antagonist Kineret (Maphis et al. 2015). Antagonism of IL-1R 
has also been shown to improve cognitive deficits in the 3xTg model of AD (Kitazawa et 
al. 2011). Finally, a recent report showed that activated microglia can induce a 
neurotoxic phenotype in astrocytes, that these activated astrocytes are present in AD 
tissue, and blockage of the transformation of astrocytes into neurotoxic astrocytes can 
be neuroprotective (Liddelow et al. 2017). Given that FKN agonism reduces pro-
inflammatory gene expression, FKN agonism may promote an environment more 
permissive to learning and memory (Lyons et al. 2009). 
Besides cytokine secretion, microglia are also directly involved in synaptic 
homeostasis. Depletion of microglia caused cognitive deficits and removal of microglial-
derived brain derived neurotrophic factor recapitulated these effects, implicating 
microglial neurotrophic support in learning and memory (Parkhurst et al. 2013). 
Furthermore, microglia are involved in synaptic engulfment, both in disease and 
homeostasis (Hong et al. 2016; Schafer et al. 2012). Microglial dysfunction and 
senescence have been implicated in AD and clearance of senescent glial cells has 
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recently been shown to improve recognition memory in the PS19 model of tauopathy 
(Bussian et al. 2018; Miller and Streit 2007). Increased FKN agonism may return 
microglia to a homeostatic state, facilitating learning. 
Interestingly, we did not observe changes in microglial pan markers (CD45 and 
IBA-1), but this is consistent with what we have observed in previous studies in 
Parkinson’s disease where we showed a neuroprotective effect of sFKN over 
expression but no concomitant reduction in MHC-II expression (Nash et al. 2015). A 
likely explanation is that we are altering the microglial state with the addition of sFKN 
rather than decreasing the level of activation, as these markers can be increased in 
both proinflammatory and alternative activated states (Lee et al. 2013). We believe that 
the sFKN subtly altered microglial activation in a such a way that is more permissive to 
learning without altering expression of either CD45 or IBA-1. We would predict that this 
altered state would be less pro-inflammatory and possibly more neuroprotective. 
To further investigate alterations in microglial activation, we examined a panel of 
immune-related genes by qPCR and observed a significant increase in Vegfa 
expression in animals over expressing sFKN (Fig. 2.9). While vascular endothelial 
growth factor (VEGF) is most known for angiogenesis, it can also impact neurogenesis 
and promote neuron survival. VEGF has been shown to protect primary hippocampal 
neurons from excitotoxicity in vitro and promote neurogenesis in vivo (Jin et al. 2002; 
Matsuzaki et al. 2001). In neurodegenerative diseases, VEGF has been shown to be 
neuroprotective in Parkinson’s disease, amyotrophic lateral sclerosis, and Alzheimer’s 
disease models (Dodge et al. 2010; Religa et al. 2013; Tian et al. 2007). 
Neuroprotective effects are mediated both by direct anti-apoptotic signaling in neurons, 
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neurogenesis, and through increased trophic support (Jin et al. 2001; Jin et al. 2002; 
Storkebaum and Carmeliet 2004; Sun et al. 2003). We hypothesize this increase in 
trophic support improved neuronal function, which may explain the improvement in 
cognitive performance observed in this study. Closer examination of the microglial 
profile with sFKN agonism is the focus of our current investigations. 
rTg4510 mice begin to show tau pathology as early as 3-4 months of age with 
behavioral deficits starting as early as 2.5 months (Dickey et al. 2009; Santacruz et al. 
2005). By 6 months of age, rTg4510s have significant insoluble tau deposits and 
marked neuron loss and behavioral deficits. Furthermore, accumulation of insoluble tau 
species plateaus from 5.5 months of age onward, as does accumulation of a 64 kDa 
soluble phospho-tau species (Dickey et al. 2009; Santacruz et al. 2005). Examining the 
tau pathology in the sFKN treated animals, we observed no significant change in 
soluble total tau or soluble phospho-tau species, but interestingly we did observe a 
significant small increase in insoluble total tau in animals over expressing sFKN. When 
we examined tau pathology by immunohistochemical means, we observed no increase 
in pSer396 phospho-tau and no increase in Gallyas-positive tau tangles. The inability of 
sFKN over expression to slow tau pathology here is possibly due to achievement of 
stable, plateau levels of pathology already present at the time of injection (Dickey et al. 
2009; Santacruz et al. 2005; Spires et al. 2006). Alternatively, it may also require higher 
elevations of sFKN than we obtained here to reduce the accumulation of tau in these 
mice.  
It is also important to note that our results are similar to those reported where the 
tau transgene expression was suppressed with doxycycline at 5.5 months of age 
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(Ramsden et al. 2005; Santacruz et al. 2005). The mice on doxycycline improved in 
spatial learning tasks at 7 and 9.5 months compared to those without doxycycline, but 
the treated mice had no reductions in neurofibrillary tangles, PHF-1 positive neurons, or 
neuron number in the CA1 subfield (Santacruz et al. 2005). The recovery of memory in 
this mouse model, by doxycycline and now sFKN treatment, suggests that irreversible 
structural degeneration may not be responsible for initial memory deficits and that there 
is potential to recover some cognitive function in early stages of the disease. Indeed, 
this uncoupling of insoluble tau deposition from neuron loss and cognitive deficits is not 
unique to this model, as NFT formation does not correlate well with neuron loss in the 
human brain (Berger et al. 2007; Gomez-Isla et al. 1997; Spires-Jones et al. 2011). This 
could open the door for some medications to have profound improvements in quality of 
life for patients and delay the need and reduce the cost of extensive residential care. It 
has been estimated that a five-year delay in AD could lead to a 40% reduction in costs 
by 2050 (Zissimopoulos et al. 2014).  
 We have previously demonstrated that sFKN can be beneficial in a preventative 
approach in rTg4510 mice with administration at three months of age, prior to significant 
pathology. Here we shown that delivery of sFKN, using AAV4, can have a beneficial 
cognitive effect in rTg4510 mice with advanced pathology, at five months of age. In this 
study, we show the utility of delivering AAV4 to the lateral ventricles and over 
expressing a soluble immunomodulator into the CSF to achieve broad delivery of a 
therapeutic gene product to treat tauopathy. We have shown that this delivery method 
can meaningfully increase sFKN concentrations in the hippocampus as well as 
ameliorate behavioral deficits in the rTg4510 mouse model of tauopathy with advanced 
 
 
51 
tau pathology. These data suggest that immunomodulation could have significant 
benefits in AD patients which already show tau pathology.  
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CHAPTER THREE: 
FKN OVER EXPRESSION PROTECTS AGAINST INSOLUBLE TAU DEPOSITION IN 
BOTH A PREVENTATIVE AND INTERVENTIONAL STUDY DESIGN 
 
Abstract 
 Fractalkine (FKN) signaling has been studied in the context of neurodegeneration 
and increased FKN agonism has been shown to be therapeutic in both Parkinson’s 
disease and tauopathy models. Here, we over express a soluble FKN ligand (sFKN) 
with recombinant adeno-associated virus in the rTg4510 mouse model of tauopathy at 
both a preventative and therapeutic timepoint. The rTg4510 model over expresses 
human tau with the frontotemporal dementia-associated mutation P301L under control 
of a tetracycline responsive element such that administering tetracycline, or its analog 
doxycycline, inhibits expression of the human tau. In order to remove potentially 
confounding effects of mutant tau expression during development, we suppressed 
expression of P301L tau with doxycycline from conception until 21 days postnatally. 
Interestingly, we observed that doxycycline treatment unfortunately delayed the model’s 
phenotype longer than the time for which the transgene was suppressed, which resulted 
in the elimination of the hyperactive phenotype and delayed emergence of cognitive 
deficits. On the few tasks where we saw a transgene effect, novel object recognition 
and RAWM reversal, sFKN expression was not able to rescue the deficit. However, 
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sFKN did protect against insoluble pSer396 phospho-tau deposition and altered the 
microglial phenotype in both study designs. 
 
Introduction 
 Fractalkine (CX3CL1; FKN) is unique among chemokines as the only member of 
the CX3C motif family and has a one-to-one relationship with its receptor, CX3CR1 
(Bazan et al. 1997; Imai et al. 1997; Pan et al. 1997). Produced as a transmembrane 
protein, FKN can undergo proteolytic cleavage by a disintegrin and metalloprotease 
(ADAM) 10/17 or cathepsin S to produce a secreted, soluble form of the protein (Garton 
et al. 2001; Hundhausen et al. 2003; Jones et al. 2013). There is evidence that the full-
length and soluble forms of FKN activate the receptor differently (Clark and Malcangio 
2012; Kim et al. 2011). In the periphery, the full-length form is important for monocyte 
adhesion to endothelial cells while the soluble form acts as a chemoattractant for 
lymphocytes and monocytes (Imai et al. 1997). In the central nervous system (CNS), 
FKN is produced by neurons and its receptor is expressed only on microglia (Cardona 
et al. 2006; Harrison et al. 1998). FKN signaling in the CNS blunts microglial activation, 
reducing production of pro-inflammatory cytokines such as interleukin (IL)-1b, IL-6, and 
tumor necrosis factor (TNF)-a (Lyons et al. 2009). 
 Fractalkine’s role in neurodegenerative diseases has been extensively studied. 
Initial work showed that disrupting FKN signaling, whether by knocking out the receptor 
or the ligand, worsened Parkinson’s disease pathology, tauopathy, and amyotrophic 
lateral sclerosis (Bhaskar et al. 2010; Cardona et al. 2006; Morganti et al. 2012). 
Interestingly, disrupting FKN signaling in amyloid depositing mice showed amelioration 
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of the pathology due to increased microglial phagocytosis of the extracellular amyloid 
plaques (Fuhrmann et al. 2010; Lee et al. 2010b; Liu et al. 2010). Studies investigating 
the over expression of FKN in Parkinson’s disease models have found the putative 
ADAM 10/17 cleavage product (sFKN; amino acids 1-336) is beneficial in multiple 
models of the disease (Morganti et al. 2012; Nash et al. 2015; Pabon et al. 2011). 
Previously, we reported a gene therapy approach using AAV-sFKN over expression 
vectors delivered to the hippocampus of the rTg4510 mouse model of tauopathy can 
reduce tau pathology, ameliorate neuron loss, and reduce microgliosis in this model 
(Nash et al. 2013). However, we were unable to rescue behavioral deficits in those 
animals, possibly due to the limited distribution of transgene expression. In this study 
we will further explore the therapeutic potential of sFKN over expression. 
 The rTg4510 mouse model of tauopathy is a doubly transgenic, regulatable 
model possessing both a tetracycline transactivator transgene (tTA), driven by a 
Ca2+/calmodulin-dependent protein kinase II (CaMKII)-a promotor, and mutant human 
tau with the dementia-associated P301L mutation under control of the tet operon 
(Santacruz et al. 2005). The CaMKIIa promoter driving tTA restricts expression of the 
human tau regionally to neocortex, hippocampus, amygdala, and basal ganglia and 
temporally to approximately post-natal day 3 (Bayer et al. 1999; Dickey et al. 2009; 
Mayford et al. 1996). However, neurodegeneration and tauopathy are more prominent 
in the cortex and hippocampus than the basal ganglia (Spires et al. 2006). These mice 
show rapid onset of tau pathology with soluble phospho-tau present as early as one 
month, MC-1 (a conformation-specific antibody) positive tau at three months, and 
sarkosyl-insoluble tau as well as Gallyas positive tangles present at 5.5 months of age 
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(Dickey et al. 2009; Santacruz et al. 2005). Behavioral deficits are observed in Morris 
water maze beginning at 4.5 months and we have reported deficits in RAWM at 5.5 
months with associated neurodegeneration beginning at 5.5 months (Nash et al. 2013; 
Santacruz et al. 2005). 
 Suppression of human P301L tau is achieved through doxycycline administration 
in this model. Suppression of transgene expression has been shown to ameliorate 
memory deficits, prevent neurodegeneration, and, before a certain timepoint, prevent 
further accumulation of PHF-1 tau (Santacruz et al. 2005; Spires et al. 2006). There are 
also reports of age-independent behavioral and anatomical effects stemming from either 
tTA or P301L expression during development in this model. Specifically, Ramsden et al. 
(2005) observed 1.3-month-old rTg3510s had an increased pathlength to find the 
platform in Morris water maze compared to P301L tau-negative littermate controls as 
well as a subtly reduced brain size. Furthermore, reduced neuron counts in the dentate 
gyrus and CA1 of the hippocampus have been observed in two-month old rTg4510s 
(Helboe et al. 2017; Spires et al. 2006). In order to more accurately assess the effects 
of increased FKN signaling on age-dependent pathological accumulation of tau and 
resulting cognitive deficits, we chose to suppress P301L tau expression in utero and 
until the pups were weaned. We then assessed the effects of FKN expression in mice 
prior to significant tau expression, at two months of age, and after insoluble tau 
deposition, at five months of age. 
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Methods 
 Adeno-associated Virus Production 
 The ectodomain of mouse fractalkine (amino acids 1-336) was isolated from 
mouse cDNA and cloned into pTR2-MCSW vector at the Age I and Nhe I sites as 
described previously (Morganti et al. 2012; Nash et al. 2013). This vector contained the 
AAV2 terminal repeats and hybrid cytomegalovirus-chicken b-actin (CBA) promoter with 
a 3’ woodchuck posttranscriptional regulatory element (Hlavaty et al. 2005). A C-
terminal hemagglutinin (HA)-tag was added for protein detection. rAAV9 particles were 
generated and quantified using a modified dot-blot method using a non-radioactive 
biotinylated probe for fractalkine generated by polymerase chain reaction as described 
previously (Burger and Nash 2016; Nash et al. 2013) 
 Transgenic Mice, Breeding, and Suppression with Doxycycline 
 Parental mutant tau and tetracycline-controlled transactivator protein strains were 
maintained separately and bred to produce rTg4510s and littermate nontransgenic 
(NonTg) and tetracycline-controlled transactivator protein (tTA) mice as previously 
described (Santacruz et al. 2005). Littermate tTA and NonTg mice were used as 
behavioral controls. Female P301L tau mice were given doxycycline (625 mg/kg) one 
week prior to pairing with tTA male mice for breeding. Dox suppression was maintained 
until the pups were weaned, 21 days after birth. Study animals were given food and 
water ad libitum and maintained on a 12-hour light/dark cycle. 
 Surgical Procedure and Tissue Collection 
 Animals were separated into two Studies (see Fig. 3.1). Animals in Study 1 
(preventative design) were randomly assigned to receive either AAV9 GFP (n=15) or 
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AAV9 sFKN (n=9) and injected at two months of age and survived to 6 months of age. 
Animals in Study 2 (therapeutic design) were randomly assigned to receive either 
AAV9 GFP (n=12) or AAV9 sFKN (n=8) and injected at five months of age and survived 
to eight months of age. Immediately before surgery, mice were weighed and 
anesthetized with isoflurane. Surgeries were performed using a stereotaxic apparatus. 
Mice were administered imipramine (3 mg/kg subcutaneously) prior to and for 48 hours 
after surgery. The cranium was exposed by an incision through the skin along the 
midsaggital plane and four holes were drilled through the cranium using a dental drill bit 
(SSW HP-3; SSWhite Burs Inc, Lakewood, NJ, USA). A Hamilton microsyringe was 
lowered and 2 µL of viral vector in sterile phosphate-buffered saline (1 x 1013 vg/mL) 
were dispensed. Study 1 animals were injected bilaterally into the hippocampus 
(coordinates from Bregma: -2.7 mm anteroposterior, ±2.7 mm lateral, & -3.0 mm 
vertical) and anterior cortex (coordinates from Bregma: 1.8 mm anteroposterior, ±2.0 
mm lateral, & -2.7 mm vertical). Study 2 animals were injected bilaterally into the 
hippocampus (coordinates from Bregma: -2.7 mm anteroposterior, ±2.7 mm lateral, & -
3.0 mm vertical) and anterior cortex (coordinates from Bregma: 2.0 mm anteroposterior, 
±2.0 mm lateral, & -3.0 mm vertical). All injections used the convection enhanced 
delivery method described previously (Carty et al. 2010; Nash and Gordon 2016). 
 Three (Study 2) or four (Study 1) months post-surgery, mice were weighed and 
overdosed with pentobarbital (200mg/kg). Mice were perfused with 25 mL of 0.9% 
normal saline on a heat pad to prevent hypothermia. Brains were collected immediately 
after perfusion. The right hemisphere was dissected and frozen on dry ice for 
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biochemical analysis. The left hemisphere was immersion fixed in 4% 
paraformaldehyde and shipped to FDNeuroTech for histochemical analysis.  
 Tissue Homogenization, ELISA, and Western Blotting 
 Anterior cortex samples were homogenized in TBS (25mM Tris, 150mM NaCl, 
pH 7.6) with protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO, USA; Cat. No. 
P8340), phosphatase inhibitor cocktails II and III (Sigma Aldrich, St. Louis, MO, USA; 
Cat. Nos. P5726 & P0044, respectively), and Benzonase (Sigma Aldrich, St. Louis, MO, 
USA; 25 U/mL final concentration) at 10 vol/wt of tissue. Tissue was homogenized with 
pestle and briefly sonicated (3 x 3 s). Samples were then centrifuged at 40,000 x g for 
30 min at 4 °C. The resulting supernatant was assayed for total protein using Pierce 
BCA protein assay (Thermo Scientific, Walthman, MA, USA) and 50 µg per sample 
used for ELISA. A Milliplex Multiplex ELISA (Millipore Sigma, Burlington, MA, US) was 
purchased and the manufacturer’s recommended protocol was followed. ELISA was 
analyzed using Bio-Plex MAGPIX (Bio-Rad Laboratories, Hercules, CA, USA). 
 Hippocampal samples were homogenized in radio-immunoprecipitation assay 
buffer (25mM Tris, 150mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-
100, pH 7.6) with protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO, USA; Cat. 
No. P8340), phosphatase inhibitor cocktails II and III (Sigma Aldrich, St. Louis, MO, 
USA; Cat. Nos. P5726 & P0044, respectively), and Benzonase (Sigma Aldrich, St. 
Louis, MO, USA; 25U/mL final concentration) at 10 vol/wt of tissue. Tissue was 
homogenized with pestle and briefly sonicated (3 x 3 s). Samples were then centrifuged 
at 40,000 x g for 30 min at 4 °C. The resulting pellet was resuspended in 70% formic 
acid (2 µL/mg tissue) and incubated for 60 min at room temperature. An equal volume 
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of 1M Tris pH 7.5 was added and the sample was neutralized to pH 7.5 with NaOH, if 
needed. The soluble fraction was taken for Western blotting and total protein 
concentration was determined by Pierce BCA protein assay (Thermo Scientific, 
Walthman, MA, USA). For Western blotting, 5 µg of protein from the soluble fraction or 2 
µg from the insoluble fraction was loaded for each sample. H150 (total tau; Sigma 
Aldrich, St. Louis, MO, USA), anti-pSer199/202 (Anaspec, Fremont, CA, USA), and anti-
pSer396 (Anaspec, Fremont, CA, USA) were used to assess tau pathology. Primary 
antibodies were used at 1:1,000 and secondary antibodies at 1:10,000 (Li-Cor 
Biosciences, Lincoln, NE, USA). All signals were normalized to a total protein stain 
(REVERT; Li-Cor Biosciences, Lincoln, NE, USA). 
 Behavioral Assessment 
 All behavioral tasks were conducted by an observer blinded to treatment 
condition and genotype of the mice. The open field was used as a general measure of 
activity and anxiety. Animals were recorded for 15 minutes in a 40 cm x 40 cm open 
field with video tracking software (ANY-Maze, Stoelting, Wood Dale, IL, USA). General 
activity levels were evaluated by distance traveled in the open field. 
 Each animal was placed for a single, 5-minute trial in a Y-maze and activity was 
recorded (ANY-Maze, Stoelting, Wood Dale, IL, USA). The number of arm entries and 
spontaneous alternation, entering each arm in sequence without repetition, was 
expressed as a percentage as previously described (Brownlow et al. 2014). 
 Short term memory was evaluated by the novel object recognition task. Two 
objects, similar in scale to the mice, were placed in the 40 cm x 40 cm open field arena 
approximately 3-5 cm from the outer wall. Each animal was given three 5-minute 
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familiarization trials with a 5-minute inter-trial interval. On the fourth trial, one of the 
objects was switched for a novel object. Animals were given five minutes to explore the 
objects and their activity was recorded (ANY-Maze, Stoelting, Wood Dale, IL, USA). The 
objects and arena were cleaned between trials with 10% ethanol to minimize olfactory 
cues. Working memory was evaluated, measuring the time spent with familiar object 
and novel object on the final trial. 
 Coordination was assessed on an accelerating rotating rod apparatus 3 cm in 
diameter. The rod was initially rotating at 4 rpm and gently accelerated to 40 rpm over 
five minutes. Mice were placed on the rod and latency to fall onto a spring-cushioned 
lever was recorded. Animals were given four trials on one day to perform this task.  
 Radial arm water maze (RAWM) has been described in detail, including sample 
score sheets, previously (Alamed et al. 2006). The radial arm water maze contained six 
arms radiating from an open central area with a hidden escape platform located at the 
end of one of the arms. Around the pool, several extra-maze cues were hung to allow 
for spatial navigation. On each trial, the mouse was allowed 60 seconds to find the 
platform. The platform was located in the same goal arm on each trial. On day one, the 
mice were given 15 trials alternating between a visible and hidden platform. On day two, 
mice were given 15 additional trials, all with a hidden platform. The start arm was varied 
for each trial, forcing mice to rely on the extra-maze spatial cues to find the platform 
instead of procedural memory. The goal arm for each mouse was different to avoid odor 
cues revealing the platform location. Entry into an incorrect arm (all four limbs in the 
arm) was counted as an error. Failure to enter an arm for 15 seconds was also counted 
as an error. The errors of blocks of three trials were averaged for data analysis. Mice 
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that made one or fewer errors on the last block of Day 2 were considered to have 
learned the platform location. 
 On the third day, a reversal trial was performed with the goal arm moved 180° 
across the pool. The mice were again given 15 trials, all with the hidden platform, to 
learn its new location. On the fourth day, the arm insert was removed from the pool, the 
extra-maze cues were taken down, and the platform was raised above the surface of 
the water with a flag attached to confirm that all mice were able to see and capable of 
ascending the platform. Latency to find and ascend the platform was recorded with a 
maximum swim time of 60s. 
 Fear-associated learning and recall was assessed using the passive avoidance 
task. Animals were placed into a two-chambered apparatus with metal rod floors. The 
left chamber was illuminated while the right chamber was kept dark. Each chamber was 
separated by a guillotine door. The animal was placed into the light chamber and 
allowed to explore for 30 seconds, at which point the guillotine door opened. Once all 
four limbs of the animal were in the dark chamber, the door was closed, and a 0.25 mA 
foot shock administered. The animal was allowed to explore the dark chamber for an 
additional 30 seconds and returned to its home cage. Twenty-four hours after training, 
the animal was again placed in the light chamber and latency to cross into the dark 
chamber was measured. No additional foot shocks were administered. 
 Statistical Analysis 
 Statistical analysis was performed using SPSS Statistics (IBM, Armonk, NY, 
USA). For rotarod, RAWM training, and Reversal training, a repeated measures 
analysis of variance (ANOVA) was performed to analyze performance for all groups 
 
 
62 
within a study. For RAWM and Reversal, total errors on each day were compared using 
a one-way ANOVA with a Fisher’s LSD post-hoc analysis to assess performance of all 
groups within a study. Time spent exploring the objects in novel object recognition was 
compared within each group by a two-tailed Student’s t-test. For tau western blotting, 
where there was no signal from mice lacking P301L tau expression, a Student’s t-test 
was performed comparing sFKN-injected rTg4510s to GFP-injected rTg4510s. Multiplex 
ELISA data was analyzed by one-way ANOVA and Fisher’s LSD comparing all groups 
within a study. The threshold for significance was set at p=0.05. 
 
 
Figure 3.1 Study design. Tg4510s were given doxycycline to suppress tau expression 
from conception to weaning. In Study 1, animals were injected bilaterally into 
hippocampus and cortex at 2 months and euthanized at 6 months of age. In Study 2, 
animals were injected bilaterally into hippocampus and cortex at 5 months and 
euthanized at 8 months of age. Animals were behaviorally assessed, and tissue 
collected at the ages shown 
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Results 
 sFKN Over Expression did not Alter Short-Term Recognition Memory 
 rTg4510s at 5-6 months of age, in the absence of dox suppression, have been 
shown to exhibit hyperactivity and be deficient in short term recognition memory tasks 
such as novel object recognition and social recognition memory (Brownlow et al. 2013; 
Brownlow et al. 2014; Joly-Amado et al. 2016). Interestingly, suppression of P301L tau 
expression with doxycycline from E0 to P21 appears to eliminate the hyperactivity 
previously reported in rTg4510s. Locomotor activity measured in both open field and Y-
maze showed no significant differences between sFKN-injected rTg4510s, GFP-injected 
rTg4510s, or uninjected tTA behavioral controls in either study design (Fig. 3.2A, Fig. 
3.2B, Fig. 3.3A, & Fig. 3.3B). Similarly, no differences between groups was observed on 
the rotarod, indicating motor performance is intact (Fig. 3.2C & Fig. 3.3C). In both Study 
1 (viral injection at two months) and Study 2 (viral injection at five months), GFP-
injected rTg4510s displayed a deficit in short-term recognition memory in the novel 
object recognition task and sFKN over expression failed to rescue this deficit in both 
studies (Fig. 3.2D & Fig. 3.3D). 
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Figure 3.2 sFKN over expression does not increase locomotor activity or improve 
novel object recognition in Study 1 mice. (A) Graph of distance travelled in open field 
shows no deficits; (B) graph of arm entries for Y maze has no differences between 
groups; (C) graph of latency to fall on accelerating rotarod shows no deficits in motor 
coordination and learning; (D) rTg4510s were deficient in the novel object recognition 
task showing no preference for the novel object (open bars) compared to the familiar 
object (black bars) compared to tTA mice and sFKN over expression did not rescue this 
impairment. Data represented as mean ± SEM, n=8-12. * denotes p<0.05 by Student’s 
t-test. 
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Figure 3.3 sFKN over expression does not increase locomotor activity or improve 
novel object recognition in Study 2 mice. (A) Graph of distance traveled in an open 
field. (B) Graph of number of arm entries in the Y maze. rTg4510s traveled the same 
distance as tTA controls in the open field (A) and entered the same number of arms as 
tTA controls in the Y-maze (B). (C) Graph of latency to fall on a rotating rod. rTg4510s 
exhibited the same level of performance on the rotating rod as uninjected tTA mice. (D) 
Graph of time spent with the familiar (black bars) and novel object (open bars) in the 
novel object recognition task. rTg4510s in Study 2 were deficient in the novel object 
recognition task showing no preference for the novel object (open bars) compared to 
the familiar object (black bars) whereas uninjected tTA mice spent more time exploring 
the novel object than the familiar object. sFKN over expression did not rescue this 
impairment. Data represented as mean ± SEM, n=9-15. * denotes p<0.05 by Student’s 
t-test. 
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Brief Suppression of P301L Expression Delayed Onset of Significant 
Cognitive Impairments in rTg4510s 
 rTg4510 mice display a profound deficit in the radial arm water maze task, 
beginning at five months of age (Nash et al. 2013). However, the treatment with 
doxycycline during development significantly reduced this phenotype, making 
interpretation of positive effects of sFKN difficult. AAV-GFP-injected rTg4510s in Study 
1 did not display a deficit on any individual day of RAWM, nor did they display a deficit 
on Reversal, making an equivalent number of total errors as uninjected tTA controls 
(Fig. 3.4A – Fig. 3.4D). However, they did not achieve criterion performance of <1 
average errors per block by the end of Day 2. AAV-GFP-injected rTg4510s in Study 2 
made a significantly greater number of total errors on Day 1 of RAWM, during 
acquisition of the task, which was rescued by sFKN over expression (Fig. 3.5B). AAV-
GFP-injected rTg4510s in Study 2 did not make significantly more total errors than 
uninjected tTA mice on Day 2 of RAWM or over the course of the two days of the task 
(Fig 3.5A & Fig. 3.5B). However, AAV-GFP-injected rTg4510s did not achieve criterion 
performance of <1 average error per block by the end of Day 2. On Reversal, AAV-
GFP-injected rTg4510s in Study 2 made significantly more total errors finding the 
platform location than uninjected tTA mice and this deficit was not improved by sFKN 
over expression (Fig. 3.5C & Fig. 3.5D). Fear-associated learning and recall was 
assessed in animals of both Studies by the passive avoidance task. We did not observe 
a significant difference in latency to cross over to the dark chamber between groups in 
either Study (data not shown). 
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Figure 3.4 Study 1 Six-month old rTg4510s were not impaired on the RAWM task. 
(A) Graph of average errors per block on Day 2 of RAWM. (B) Graph of total errors 
made on Day 1, Day 2, and across Days 1 & 2 of the RAWM task. rTg4510s in Study 1 
performed similarly to uninjected tTA behavioral controls on the RAWM task. (C) Graph 
of average errors per block on Reversal. (D) Graph of total errors made on Reversal. 
rTg4510s performed similarly to uninjected tTA mice on Reversal. Data represented as 
mean ± SEM, n=8-12. 
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Figure 3.5 sFKN over expression in Study 2 modestly improves RAWM 
performance but not performance on Reversal. (A) Graph of average errors per 
block on Day 2 of RAWM. (B) Graph of total errors made on Day 1, Day 2, and across 
Days 1 & 2 of the RAWM task. AAV-GFP-injected rTg4510s made significantly more 
total errors on Day 1 of RAWM than AAV-sFKN-injected rTg4510s or uninjected tTA 
controls. (C) Graph of average errors per block on Reversal. (D) Graph of total errors 
made on Reversal. AAV-GFP-injected and AAV-sFKN-injected rTg4510s made 
significantly more total errors on Reversal than uninjected tTA mice. Data represented 
as mean ± SEM, n=9-15. * denotes p<0.05 by Fisher’s LSD. 
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 sFKN Over Expression Reduces Tau Phosphorylation 
 The rTg4510 mouse model of tauopathy displays robust pathological tau burden 
(Dickey et al. 2009; Santacruz et al. 2005). As we previously reported, sFKN over 
expression is capable of suppressing phospho-tau pathology when injected just at the 
onset of pathology (Nash et al. 2013). In order to confirm our previous findings and to 
extend the efficacy of sFKN as a potential therapeutic beyond a preventative 
administration, we examined the phospho-tau species pSer199/202, an early 
phosphorylation event, and pSer396, a late-stage event. Consistent with our previous 
results, injection of AAV-sFKN into 2-month old rTg4510s significantly reduced soluble 
pSer396 phospho-tau but not pSer199/202 phospho-tau or total tau (H150; Fig. 3.6A & 
Fig. 3.6B). Furthermore, AAV-sFKN-injected rTg4510s had significantly less insoluble 
pSer396 phospho-tau compared to AAV-GFP-injected rTg4510s (Fig. 3.6C & Fig. 3.6D). 
In Study 2, animals injected with AAV-sFKN after the onset of insoluble tau 
deposition displayed a trend for reduced soluble pSer396 phospho-tau and no change 
in soluble total tau levels (Fig. 3.7A & Fig. 3.7B). Interestingly, sFKN over expression in 
Study 2 significantly increased pSer199/202 phospho-tau compared to AAV-GFP-
injected rTg4510 mice. In Study 2, sFKN over expression also reduced insoluble 
pSer396 phospho-tau levels but did not change total insoluble tau (Fig. 3.7C & Fig. 
3.7D). Thus, sFKN over expression impacts tau pathology both prior to and after the 
onset of tau deposition. 
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Figure 3.6 sFKN over expression significantly reduced pSer396 phospho-tau in 
Study 1. (A) Graph of soluble total tau (H150) and phosphorylated tau at Serine 
199/202 (pS199/202) and Serine 396 (pS396) detected by western blot. (B) 
Representative blots of monomeric tau at 55 kDa for each marker. AAV-sFKN-injected 
rTg4510s had significantly lower levels of pSer396 than AAV-GFP-injected rTg4510s. 
(C) Graph of insoluble total tau (H150) and phosphorylated tau at Serine 396 (pS396) 
detected by western blot. (D) Representative blots of monomeric tau at 55 kDa for each 
marker. AAV-sFKN-injected rTg4510s had significantly lower levels of pSer396 than 
AAV-GFP-injected rTg4510s. Intensity of blots from all animals were averaged and 
converted to fold change for display. Data represented as mean ± SEM, n=8-12. * 
denotes p<0.05; *** denotes p<0.001 by two-tailed Student’s t-test. 
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Figure 3.7 sFKN over expression in Study 2 significantly differentially altered 
phospho-tau. (A) Graph of soluble total tau (H150) and phosphorylated tau at Serine 
199/202 (pS199/202) and Serine 396 (pS396) detected by western blot. (B) 
Representative blots of monomeric tau at 55 kDa for each marker. AAV-sFKN-injected 
rTg4510s had significantly higher levels of pSer199/202 and there was a trend for lower 
pSer396 levels compared to AAV-GFP-injected rTg4510s. (C) Graph of insoluble total 
tau (H150) and phosphorylated tau at Serine 396 (pS396) detected by western blot. (D) 
Representative blots of monomeric tau at 55 kDa for each marker. AAV-sFKN-injected 
rTg4510s had significantly lower levels of pSer396 than AAV-GFP-injected rTg4510s. 
Intensity of blots from all animals were averaged and converted to fold change for 
display. Data represented as mean ± SEM, n=9-15. * denotes p<0.05; ** denotes 
p<0.01 by two-tailed Student’s t-test. 
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 sFKN Over Expression Elevates Anti-Inflammatory Cytokines 
 Microglial activation is known to promote tau phosphorylation in several 
tauopathy models (Bhaskar et al. 2010; Lee et al. 2010a). FKN signaling has been 
shown to significantly reduce production of pro-inflammatory cytokines (Lyons et al. 
2009). In order to evaluate the activation state of microglia after sFKN over expression, 
we assessed several pro-inflammatory and anti-inflammatory cytokines by ELISA. 
Surprisingly, IL-1b was not elevated in AAV-GFP-injected rTg4510s compared to 
uninjected tTA mice and TNFa was undetectable by this assay in all groups in both 
studies. At both ages, sFKN significantly increased IL-10 and, in Study 1, VEGF was 
also significantly elevated, indicating a shift towards a wound-healing phenotype in the 
microglia (Fig. 3.8 & Fig. 3.9). 
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Figure 3.8 sFKN over expression altered microglial phenotype in Study 1. (A) 
Graph of IL-10 concentrations in brain homogenate. (B) Graph of VEGF concentrations 
in brain homogenate. (C) Graph of IL-1b concentrations in brain homogenate. AAV-
sFKN-injected rTg4510s in Study 1 had significantly increased concentrations of the 
anti-inflammatory cytokines IL-10 (A) and VEGF (B) compared to AAV-GFP-injected 
rTg4510s. However, sFKN over expression did not alter IL-b expression compared to 
either GFP-injected rTg4510s or uninjected tTA mice (C). Expression of all three 
cytokines were unchanged in AAV-GFP-injected rTg4510s compared to uninjected tTA 
controls. Data represented as mean ± SEM, n=8-12. * denotes p<0.05; ** denotes 
p<0.01 by Fisher’s LSD. 
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Figure 3.9 sFKN over expression altered microglial phenotype in Study 2. (A) 
Graph of IL-10 concentrations in brain homogenate. (B) Graph of VEGF concentrations 
in brain homogenate. (C) Graph of IL-1b concentrations in brain homogenate. AAV-
sFKN-injected rTg4510 mice had significantly increased IL-10 expression (A) and a 
trend for increased VEGF expression (B) compared to GFP-injected rTg4510 mice. 
However, sFKN over expression did not alter IL-b expression compared either to GFP-
injected control rTg4510s or uninjected tTA mice (C). Expression of all three cytokines 
were unchanged in AAV-GFP-injected rTg4510s compared to uninjected tTA controls. 
Data represented as mean ± SEM, n=9-15. ** denotes p<0.01 by Fisher’s LSD. 
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Discussion 
 Our previous work showed that increased FKN signaling can reduce tauopathy in 
rTg4510 mice when administered prior to the onset of neuron loss and significant 
pathology (Nash et al. 2013). However, it remained unclear if an immunomodulatory 
approach would succeed when applied after insoluble tau deposition had begun. Here, 
we aimed to both replicate our previous findings while also addressing the hypothesis 
that increased FKN signaling can reduce phospho-tau pathology even after the onset of 
significant tau pathology. Furthermore, we increased the number of injected brain 
regions in an effort to assess the impact of sFKN over expression on the cognitive 
deficits in rTg4510s. In our previous study, the animals were injected solely in the 
hippocampi and did not show an improvement in cognitive performance on the RAWM 
task (Nash et al. 2013). 
 In this study, we injected rTg4510 mice at two ages: two-months of age (prior to 
the onset of significant pathology) and five-months of age (after insoluble tau deposition 
has begun). Animals were treated with doxycycline to suppress P301L tau expression 
until after weaning at 21 days post-partum. When we assessed the behavioral 
phenotype, we were surprised to observe an absence of hyperactivity in the AAV-GFP-
injected rTg4510s, a readily apparent phenotype we have observed previously 
(Brownlow et al. 2013; Brownlow et al. 2014; Joly-Amado et al. 2016). We further 
assessed coordination on the rotarod task and found no deficits in our model. This 
suggests that we delayed tau pathology significantly longer than the corresponding 
amount of P301L tau transgene suppression. 
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Similarly, working memory deficits have been reported in rTg4510s (Brownlow et 
al. 2013; Brownlow et al. 2014). These deficits in recognition memory on the novel 
object recognition task were intact in our model, although sFKN over expression did not 
ameliorate this deficit in either study. This is consistent with our previous report in which 
intracerebroventricular injection of AAV4 sFKN improved performance on social 
recognition memory but not novel object recognition. 
After assessment of spatial learning and memory using the radial arm water 
maze task, we were surprised to observe no deficit in Study 1 and a much milder 
impairment in Study 2 than has been reported in rTg4510s not treated with doxycycline 
(Nash et al. 2013; Ramsden et al. 2005). In Study 1, we observed no statistically 
significant deficits in performance on either RAWM or Reversal when comparing AAV-
GFP-injected rTg4510s with uninjected tTA control mice. In Study 2, there was a slight 
deficit in total errors on Day 1, which was rescued by sFKN over expression. AAV-GFP-
injected rTg4510s in Study 2 made significantly more errors on the Reversal portion of 
RAWM than tTA control mice. However, sFKN over expression was unable to improve 
performance on Reversal. These improvements due to sFKN over expression are in 
keeping with our previous findings in which intracerebroventricular injection of AAV4 
sFKN improved RAWM performance, but not performance on Reversal. 
The significant delay in development of cognitive deficits after only three weeks 
of doxycycline suppression was surprising. We would have predicted only a 1-2 month 
delay in pathology and behavioral deficits since the CaMKIIa promoter driving the tTA 
expression should not be active until approximately P3 (Bayer et al. 1999). Our data 
suggests that there may be expression of the tau transgene during embryonic 
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development, which has significant effects on pathology development during adulthood. 
These observations implicate the timing of human tau expression, and not the duration 
per se, was determining manifestation and speed of onset of tau pathology and 
cognitive deficits in rTg4510s in the absence of early doxycycline suppression. 
Over expression of P301L tau early in life may interfere with neuronal 
development, accelerating cognitive decline and pathology. It has been shown that both 
tau expression and tau phosphorylation increase during development (Brion et al. 1994; 
Caceres and Kosik 1990). Furthermore, a decrease in phospho-tau levels from one to 
three months of age followed by a resurgence in phospho-tau by five months of age has 
been reported in the rTg4510 model (Dickey et al. 2009). By disrupting this interaction 
between highly phosphorylated endogenous mouse tau and pathogenic, pro-aggregant 
mutant human tau, we may have prevented the formation of toxic soluble tau species 
during development. This early formation may normally seed further pathological tau 
develop in later months, perhaps explaining the lack of significant cognitive deficits 
observed in this study. These observations highlight the need to be aware of pathology- 
or age-independent effects on normal biology by transgene over expression during 
development. 
Interestingly, after completion of a significant portion of this study, another group 
published similar findings. Helboe et al. (2017) reported suppressing transgene 
expression from conception to 6 weeks of age showed a significant delay, of up to six 
months, in the initiation of AT8-positive tau in this model. Furthermore, there was no 
thinning of the CA1 layer at that time point, even though pathology levels were similar. 
Other studies report early neuron loss in the dentate gyrus and CA1, reduced brain 
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weight, and deficits in spatial navigation beginning as early as two months in this model 
(Helboe et al. 2017; Ramsden et al. 2005; Santacruz et al. 2005; Spires et al. 2006). 
Suppression of transgene expression was able to halt this early neuron loss; however 
longitudinal analysis of the effects of early transgene suppression on cognitive 
performance was not performed. Helboe et al. (2017) postulated that the expression of 
4R tau postnatally could interfere with the function of endogenous 3R tau, causing 
inappropriate stabilization of microtubules and neuronal loss at this early timepoint. 
However, this does not explain the significant delay in tau phosphorylation after brief 
doxycycline treatment. Future experiments suppressing P301L transgene expression 
from conception to weaning should take into account the significant delay in the 
appearance of cognitive deficits and tau pathology. 
 Examining tau pathology in the sFKN treated animals by Western blot, we 
observed a significant reduction of pSer396 phospho-tau, thought to be a late-stage 
phosphorylation event occurring just prior to neurofibrillary tangle formation, in the 
young cohort of mice (Study 1). Consistent with our previous findings, this reduction 
was observed in both the soluble (~50% reduction) and insoluble (~75% reduction) 
fractions. In the older cohort of mice (Study 2), there was a strong trend for a reduction 
in soluble pSer396 (~45% reduction, p=0.057) and a significant reduction of pSer396 in 
the insoluble fraction (~60% reduction). However, in Study 2, we observed a significant 
increase (~30%) in soluble pSer199/202 whereas Study 1 showed no change. We did 
not observe significant changes in either soluble or insoluble total tau in either study, 
consistent with our previous work (Nash et al. 2013). Taken as a whole, these data 
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imply that increased FKN agonism can protect against deposition of insoluble, 
hyperphosphorylated tau. 
 A preponderance of evidence implicates neuroinflammation and microglial 
activation in Alzheimer’s disease pathogenesis (Heppner et al. 2015). Specifically, 
previous studies have shown that increasing inflammation exacerbates tau pathology 
and FKN signaling has been shown to alter microglial activation (Lyons et al. 2009; 
Morganti et al. 2012; Nash et al. 2013). Here, we examined fifteen cytokines in a 
multiplex ELISA to assess the activation state of microglia. However, only a select few 
were detectable in our sample. We observed a significant increase in IL-10 expression 
in both the younger and older cohorts of mice, as well as a significant elevation of VEGF 
in Study 1 with a trend for increased VEGF in the Study 2. This may suggest a shift in 
microglial activation away from a pro-inflammatory state. 
Further work needs to be done to identify both the phenotype of microglia in a 
tauopathy model and the microglial phenotype resulting from FKN over expression to 
gain a better understanding of how FKN exerts its protective effects. Previous reports 
have identified both IL-1b and TNFa as regulators of neurodegeneration and synaptic 
function (Bhaskar et al. 2010; Cardona et al. 2006; Maphis et al. 2015; Patel et al. 2005; 
Rogers et al. 2011; Stellwagen and Malenka 2006; Tarkowski et al. 2003). However, we 
found IL-1b was not elevated in our tauopathy model and TNFa was undetectable in our 
assay. 
 This study validates our previous findings showing the ability of increased FKN 
signaling to reduce phospho-tau pathology and expands this finding to include a 
treatment timepoint after the onset of tau deposition. This study also highlights the 
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surprising effects of brief suppression of P301L expression in Tg4510s during 
development. Previous work identified age-independent behavioral effects of tau over 
expression manifested as a deficit in spatial navigation and reduced neuron number in 
CA1 (Ramsden et al. 2005; Santacruz et al. 2005; Spires et al. 2006). By suppressing 
tau expression briefly during development, we unexpectedly delayed the onset of 
significant cognitive deficits by greater than the amount of time the transgene was 
suppressed. Finally, we assed that sFKN over expression nudges microglia away from 
a detrimental, pro-inflammatory phenotype, increasing expression of anti-inflammatory 
cytokines. 
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CHAPTER FOUR: 
CONCENTRATION AND PROTEOLYSIS OF CX3CL1 MAY REGULATE THE 
MICROGLIAL RESPONSE TO CX3CL1 
 
Abstract 
 Fractalkine (FKN) is a membrane-bound chemokine that can be cleaved by the 
proteases ADAM 10, ADAM 17, and cathepsin S to generate soluble fragments. Both 
membrane-bound and soluble FKN have been shown to have different functional roles 
in the periphery and are a number of conflicting studies within the central nervous 
system suggest that different soluble fragments may have dissimilar functional effects in 
vivo. Therefore, in this study we aimed to elucidate if there are differences in signaling 
for a full length soluble FKN (sFKN) versus a chemokine domain only peptide (ckFKN), 
which are currently used in the literature. We demonstrate that the sFKN exhibited a 
lower EC50 than the ckFKN. Interestingly, we also observed that high concentrations of 
FKN, regardless of cleavage variant, are ineffective at reducing pro-inflammatory 
microglial activation. We show that FKN may signal through an alternative receptor at 
high concentrations, suggesting an as yet unidentified signaling pathway for FKN. We 
show that the chemokine domain was not able to rescue pathology in the Tg4510 
mouse, as was previously published with the full length soluble FKN. These data may 
clarify conflicts in the literature and demonstrate that care must be taken with respect to 
in vitro and in vivo studies using FKN. 
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Introduction 
 Fractalkine (CX3CL1; FKN) is a unique chemokine, the only member of the 
CX3C motif family, which unlike other inflammatory signaling molecules has a one-to-
one relationship with its receptor (CX3CR1) (Bazan et al. 1997; Imai et al. 1997; Pan et 
al. 1997). Fractalkine is a transmembrane protein with its chemokine domain attached 
to a long, mucin-like stalk followed by a transmembrane domain and short intracellular 
domain. Fractalkine is capable of signaling as either a membrane bound protein, or it 
can be cleaved to generate a soluble fragment. Several proteases have been identified 
as generating soluble variants of FKN, such as a disintegrin and metalloprotease 
(ADAM) 10, ADAM 17, and cathepsin S (Clark et al. 2009; Garton et al. 2001; 
Hundhausen et al. 2003). While FKN and its receptor are expressed in both the 
periphery and central nervous system (CNS), in the CNS fractalkine is expressed 
primarily by neurons and its receptor expressed exclusively on microglia (Cardona et al. 
2006; Tarozzo et al. 2003). Fractalkine signaling, either through the membrane bound 
or soluble variants, has been shown to reduce expression of pro-inflammatory genes, 
such as interleukin (IL)-1b, tumor necrosis factor- (TNF) a, and IL-6, in activated 
microglia (Lyons et al. 2009; Zujovic et al. 2000; Zujovic et al. 2001). 
Since FKN can impact microglial activation, the role of FKN signaling has been 
investigated in several models of neurodegeneration and CNS insult. Genetic disruption 
of FKN signaling was found to worsen pathology in a model of tauopathy, increase 
susceptibility to LPS-induced neurotoxicity, worsen disease phenotype in a model of 
amyotrophic lateral sclerosis, and increase susceptibility of dopaminergic neurons in 
several models of Parkinson’s disease (Bhaskar et al. 2010; Cardona et al. 2006; Cho 
 
 
83 
et al. 2011; Morganti et al. 2012). However, studies have also found disrupting FKN 
signaling is neuroprotective in models of amyloid deposition and stroke (Cipriani et al. 
2011; Fuhrmann et al. 2010; Fumagalli et al. 2013; Lee et al. 2010b). 
Studies examining the neuroprotective potential of FKN in PD have suggested 
that it is the ADAM10/17 cleavage variant (sFKN; aa 1-336) that confers 
neuroprotection and not the membrane-bound FKN. Using adeno-associated virus 
(AAV) over expression of either sFKN (ADAM10/17 cleavage variant) or obligate 
membrane-bound FKN (mFKN, with the ADAM10/17 cleavage site mutated to prevent 
cleavage), only the sFKN construct showed neuroprotection from both MPTP and a-
synuclein toxicity. Thus, in PD it appears that sFKN, and not the membrane bound 
version, is the neuroprotective species (Morganti et al. 2012; Nash et al. 2015). 
However, results have been mixed in models of Alzheimer’s disease. Nash et al. 
(2013) demonstrated that over expression of sFKN was neuroprotective in the rTg4510 
mouse model of tauopathy. Over expression of sFKN reduced tau hyperphosphorylation 
and ameliorated the attendant neuron loss in this model. However, Lee et al. (2014) 
argued that the membrane bound form of FKN is required for mediating the opposing 
effects of FKN on amyloid and tau pathologies. Previously, they reported that genetic 
knockout of Cx3cr1 causes clearance of amyloid plaques in APP/PS1 mice while 
accelerating tau pathology and behavioral deficits in the hTau model of tauopathy 
(Bhaskar et al. 2010; Lee et al. 2010b). Most recently, they have shown that mice 
expressing only the chemokine domain of FKN (Cx3cl1105Δ) were crossed with 
APP/PS1 and hTau mice, creating disease models lacking membrane-bound FKN. Lee 
et al. (2014) observed chemokine domain FKN (ckFKN) expression failed to reduce the 
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Ab phagocytosis or tau phosphorylation observed in APP/PS1;Cx3cl1-/- mice. Similarly, 
Bemiller et al. (2018) reported that lack of membrane-bound FKN signaling fails to 
protect against tauopathy, microglial activation, and cognitive deficits in the hTau model 
of tauopathy compared to hTau;Cx3cl1-/- mice. These effects were attributed to a 
reduction in surface expression of CX3CR1. Therefore, the authors concluded that loss 
of membrane bound FKN signaling was responsible for the clearance of amyloid and 
exacerbation of tauopathy previously observed. Given that the authors did not express 
the membrane bound FKN, it does question if the failure was due to the lack of sFKN 
signaling, which had previously been shown to be important in neuroprotection 
(Morganti et al. 2012; Nash et al. 2013). 
Differential signaling caused by sFKN and ckFKN has been reported in studies of 
neuropathic pain. It has been observed that fractalkine expression and concomitant 
microglial activation increases in models of nerve injury and that blockage of FKN 
signaling can alleviate allodynia in these models (Milligan et al. 2004; Sun et al. 2013). 
Infusion of sFKN, which includes the mucin-like stalk, does not cause mechanical 
allodynia whereas infusion of the ckFKN significantly increased mechanical allodynia 
(Clark and Malcangio 2012). Furthermore, cathepsin S (Cat S) inhibitors demonstrated 
the involvement of Cat S in the cleavage and release of FKN during spinal injury. Cat S 
generates a fragment that migrates at a lower molecular weight than the ADAM10/17 
cleavage product, suggesting a fragment closer in size to the chemokine domain only 
(Clark et al. 2009; Fonovic et al. 2013). Calcium imaging data has also shown that the 
chemokine domain elicits reduced calcium mobilization compared to sFKN (Clark and 
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Malcangio 2012). These data imply that the microglial response to sFKN signaling may 
be different from ckFKN signaling. 
In order to further investigate the differential effects of these two FKN ligands on 
CX3CR1 signaling, we utilized receptor binding assays and functional assays in primary 
microglia. We found sFKN had a lower EC50 than ckFKN. Furthermore, we observed 
that FKN signaling at high concentrations loses its ability to reduce production of TNFa 
in LPS-stimulated primary microglia. Our data indicate this may not be entirely 
explained by a loss of signaling due to receptor internalization, and we suggest that high 
concentrations of FKN may cause signaling through a non-canonical pathway. Finally, 
we show that over expression of ckFKN in the rTg4510 model of tauopathy elevates 
basal tau levels and impairs cognition, further highlighting the differences between 
ckFKN and sFKN signaling. 
 
Methods 
 Animals  
Study animals were given food and water ad libitum and maintained on a 12-hour 
light/dark cycle. All procedures performed in studies involving animals were in 
accordance with the ethical standards of the institution at which studies were 
conducted. Two-month old Sprague-Dawley rats were purchased from Envigo for use in 
this study. Parental mutant tau (Tg(tauP301L)4510) and tetracycline-controlled 
transactivator protein (CaMKII-tTA) strains were maintained separately and bred to 
produce rTg4510s and littermate nontransgenic (NonTg) and tetracycline-controlled 
transactivator protein (tTA) mice as previously described (Santacruz et al. 2005). 
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Littermate tTA and NonTg mice were used as behavioral controls. Female P301L tau 
mice were given doxycycline (625 mg/kg) one week prior to pairing with tTA male mice 
for breeding. Dox suppression was maintained until the pups were weaned, 21 days 
after birth. 
Adeno-associated Virus Production 
The chemokine domain (amino acids 1 – 105) of mouse fractalkine was isolated 
from mouse cDNA and cloned into pTR2-MCS vector at the Age I and Nhe I sites as 
described previously (Morganti et al. 2012; Nash et al. 2013). This vector contained the 
AAV2 terminal repeats and hybrid cytomegalovirus-chicken b-actin (CBA) promoter. A 
C-terminal hemagglutinin (HA)-tag was added for protein detection. rAAV9 particles 
were generated as described previously (Carty et al. 2010) and quantified using a dot-
blot method with a non-radioactive biotinylated probe for fractalkine generated by 
polymerase chain reaction (Burger and Nash 2016; Nash et al. 2013). 
 Animal Surgery and Tissue Collection 
 rTg4510s were randomly assigned to receive either AAV9 GFP (n=12) or AAV9 
ckFKN (n=8) and injected at five months of age and survived to eight months of age. 
Immediately before surgery, mice were weighed and anesthetized with isoflurane. 
Surgeries were performed using a stereotaxic apparatus. Mice were administered 
imipramine (3 mg/kg subcutaneously) prior to and for 48 hours after surgery. The 
cranium was exposed by an incision through the skin along the midsaggital plane and 
four holes were drilled through the cranium using a dental drill bit (SSW HP-3; SSWhite 
Burs Inc, Lakewood, NJ, USA). A Hamilton microsyringe was lowered and 2 µL of viral 
vector in sterile phosphate-buffered saline (1 x 1013 vg/mL) were dispensed. Animals 
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were injected bilaterally into the hippocampus (coordinates from bregma: -2.7 mm 
anteroposterior, ±2.7 mm lateral, & -3.0 mm vertical) and anterior cortex (coordinates 
from bregma: 2.0 mm anteroposterior, ±2.0 mm lateral, & -3.0 mm vertical). All 
injections used the convection enhanced delivery method described previously (Carty et 
al. 2010; Nash and Gordon 2016). 
 Three months post-surgery, mice were weighed and overdosed with 
pentobarbital (200mg/kg). Mice were perfused with 25 mL of 0.9% normal saline on a 
heat pad to prevent hypothermia. Brains were collected immediately after perfusion. 
The right hemisphere was dissected and frozen on dry ice for biochemical analysis. The 
left hemisphere was immersion fixed in 4% paraformaldehyde and shipped to 
FDNeuroTech for histochemical analysis. 
 Tissue Homogenization and Western Blotting 
 Hippocampal samples were homogenized in radio-immunoprecipitation assay 
buffer (25mM Tris, 150mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-
100, pH 7.6) with protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO, USA; Cat. 
No. P8340), phosphatase inhibitor cocktails II and III (Sigma Aldrich, St. Louis, MO, 
USA; Cat. Nos. P5726 & P0044, respectively), and Benzonase (Sigma Aldrich, St. 
Louis, MO, USA; 25U/mL final concentration) at 10 vol/wt of tissue. Tissue was 
homogenized with pestle and briefly sonicated (3 x 3 s). Samples were then centrifuged 
at 40,000 x g for 30 min at 4 °C. The resulting pellet was resuspended in 70% formic 
acid (2 µL/mg tissue) and incubated for 60 min at room temperature. An equal volume 
of 1M Tris pH 7.5 was added and the sample was neutralized to pH 7.5 with NaOH, if 
needed. The soluble fraction was taken for Western blotting and total protein 
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concentration was determined by Pierce BCA protein assay (Thermo Scientific, 
Walthman, MA, USA). For Western blotting, 5 µg of protein from the soluble fraction or 2 
µg from the insoluble fraction was loaded for each sample. H150 (total tau; Sigma 
Aldrich, St. Louis, MO, USA), anti-pSer199/202 (Anaspec, Fremont, CA, USA), and anti-
pSer396 (Anaspec, Fremont, CA, USA) were used to assess tau pathology. Primary 
antibodies were used at 1:1,000 and secondary antibodies at 1:10,000 (Li-Cor 
Biosciences, Lincoln, NE, USA). All signals were normalized to a total protein stain 
(REVERT; Li-Cor Biosciences, Lincoln, NE, USA). 
 Behavioral Assessment 
 All behavioral tasks were conducted by an observer blinded to treatment 
condition and genotype of the mice. The open field was used as a general measure of 
activity and anxiety. Animals were recorded for 15 minutes in a 40 cm x 40 cm open 
field with video tracking software (ANY-Maze, Stoelting, Wood Dale, IL, USA). General 
activity levels were evaluated by distance traveled in the open field. 
 Short term memory was evaluated by the novel object recognition task. Two 
objects, similar in scale to the mice, were placed in the 40 cm x 40 cm open field arena 
approximately 3-5 cm from the outer wall. Each animal was given three 5-minute 
familiarization trials with a 5-minute inter-trial interval. On the fourth trial, one of the 
objects was switched for a novel object. Animals were given five minutes to explore the 
objects and their activity was recorded (ANY-Maze, Stoelting, Wood Dale, IL, USA). The 
objects and arena were cleaned between trials with 10% ethanol to minimize olfactory 
cues. Working memory was evaluated, measuring the time spent with familiar object 
and novel object on the final trial. 
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 Radial arm water maze (RAWM) has been described in detail, including sample 
score sheets, previously (Alamed et al. 2006). The radial arm water maze contained six 
arms radiating from an open central area with a hidden escape platform located at the 
end of one of the arms. Around the pool, several extra-maze cues were hung to allow 
for spatial navigation. On each trial, the mouse was allowed 60 seconds to find the 
platform. The platform was located in the same goal arm on each trial. On day one, the 
mice were given 15 trials alternating between a visible and hidden platform. On day two, 
mice were given 15 additional trials, all with a hidden platform. The start arm was varied 
for each trial, forcing mice to rely on the extra-maze spatial cues to find the platform 
instead of procedural memory. The goal arm for each mouse was different to avoid odor 
cues revealing the platform location. Entry into an incorrect arm (all four limbs in the 
arm) was counted as an error. Failure to enter an arm for 15 seconds was also counted 
as an error. The errors of blocks of three trials were averaged for data analysis. Mice 
that made one or fewer errors on the last block of Day 2 were considered to have 
learned the platform location. 
 On the third day, a reversal trial was performed with the goal arm moved 180° 
across the pool. The mice were again given 15 trials, all with the hidden platform, to 
learn its new location. On the fourth day, the arm insert was removed from the pool, the 
extra-maze cues were taken down, and the platform was raised above the surface of 
the water with a flag attached to confirm that all mice were able to see and capable of 
ascending the platform. Latency to find and ascend the platform was recorded with a 
maximum swim time of 60s. 
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Microglial Isolation 
 Sprague-Dawley rats, aged 2-6 months, were used in this study. Animals were 
deeply anesthetized with pentobarbital (200mg/kg) and transcardially perfused with 50 
mL of 0.9% saline. Whole brains were mechanically homogenized with a razor blade 
followed by enzymatic digestion as described previously (Garcia et al. 2014). 
Undigested debris were removed by passage through a 70 µm filter. Cells were 
resuspended in 70% isotonic percoll and myelin removed. Microglia were labelled with 
magnetic beads conjugated to anti-CD11b/c antibodies. Labelled cells were isolated 
using magnetic separation (Miltenyi Biotech, Auburn, CA, USA). Cells were plated into a 
96-well plate at a seeding density of 5x105 cells/well and cultured in DMEM:F12 with the 
following additives: 10% fetal bovine serum, 1% penicillin/streptomycin, and 50 ng/µL 
rat GM-CSF (PeproTech, Rocky Hill, NJ, USA). Cells were cultured for 48 hours at 37 
°C under 5% CO2 prior to treatment. 
 Fractalkine Treatments and ELISA 
 All dilutions were made in basal media. Recombinant human soluble fractalkine 
(hsFKN; aa 25-339) and recombinant human fractalkine chemokine domain peptide 
(hckFKN; aa 25-100) were purchased from R&D Systems, Minneapolis, MN, USA. 
Fractalkine-containing medium (or vehicle) was added and incubated for 15 minutes 
prior to the addition of LPS (Sigma Aldrich, St. Louis, MO, USA). LPS was added to a 
final concentration of 1 ng/mL and cells were incubated for 3 hours at 37 °C under 5% 
CO2. Media was collected and assayed for tumor necrosis factor (TNF)a by ELISA per 
the manufacturer’s recommended protocol (R&D Systems, Minneapolis, MN, USA). 
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 Flow Cytometry 
 Acutely isolated cells were treated with fractalkine (or vehicle) for 3 hours at 
37 °C under 5% CO2. Cells were washed and stained with Zombie Violet, a fixable 
live/dead marker, at 1:100 in PBS for 30 minutes on ice (Biolegend, San Diego, CA, 
USA). Cells were fixed in 2% paraformaldehyde for 15 minutes on ice, Fc receptors 
blocked with 10% donkey serum in PBS (flow buffer) and subsequently stained with 
rabbit anti-CX3CR1 (1:100 in flow buffer) or rabbit polyclonal IgG isotype control (1:100 
in flow buffer) for 30 minutes on ice. Cells were washed and incubated with a donkey 
anti-rabbit antibody conjugated to Alexa 647 (1:1000 in flow buffer) for 30 minutes on 
ice. CD11b/c-positive cells were identified by incubating with FITC-conjugated Reagent 
Check at 1:11 in flow buffer for 10 minutes on ice (Miltenyi Biotech, Auburn, CA, USA). 
Samples were analyzed on BD LSR II (Becton Dickinson, San Jose, CA, USA). The 
live/dead marker was excited at 404 nm and measured at 450/50 nm. FITC-Reagent 
Check was excited at 488 nm and measured at 510/20 nm. Alexa 647 was excited at 
640 nm and measured at 670/14 nm. The results were analyzed on BD FacsDiva6.1.3 
software (Becton Dickinson, San Jose, CA, USA). 
 Beta-Arrestin Screen 
 PathHunter eXpress CX3CR1 CHO-K1 b-arrestin GPCR Assay was purchased 
from DiscoverX (Fremont, CA, USA) and the manufacturer’s recommended protocol 
followed. Briefly, cells were plated into a white-walled, clear-bottom 96-well plate and 
cultured for 48 hours prior to treatment. Cells were treated with hsFKN or hckFKN for 90 
minutes at 37 °C under 5% CO2. Substrate reagent was added, and cells incubated for 
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60 minutes at room temperature. Luminescence read on BioTek Cytation3 (BioTek, 
Winooski, VT, USA). 
 Statistical Analysis 
 Statistical analysis was performed using SPSS Statistics (IBM, Armonk, NY, 
USA). For behavioral tasks, a one-way analysis of variance (ANOVA) was performed 
with Fisher’s LSD post-hoc analyzing all three groups. For radial arm water maze and 
reversal training, a repeated measures ANOVA was used to assess learning across 
time analyzing all three groups. For western blotting, where there is no signal from mice 
lacking P301L tau expression, a two-tailed Student’s t-test was used. 
For FKN dose-response in LPS-stimulated primary microglia, a one-way ANOVA 
and Fisher’s LSD was used to compare between concentrations of one FKN species. 
For all other FKN-treated primary microglia screens, a two-tailed Student’s t-test was 
used. To compare control-treated wells to LPS alone, a one-way ANOVA with Dunnett’s 
post-hoc was used. The threshold for a significant finding was set at p=0.05. 
 
Results 
 Different Fractalkine Ligands have Different Receptor Affinities 
 In order to investigate any potential differences in receptor affinity of these two 
constructs, we utilized a reporter cell line expressing the fractalkine receptor. In this 
reporter line, stimulation of the receptor causes b-arrestin/b-galactosidase fusion-protein 
to associate with the receptor and subsequent activation of b-galactosidase, which, 
when combined with substrate, luminesces (Fig 4.1 A). We observed that the 
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chemokine domain of FKN has approximately 10-fold greater EC50 (4.2 nM) than the 
full-length soluble FKN (0.38 nM) (Fig 4.1 B). 
 
Figure 4.1 hsFKN has greater affinity for CX3CR1 than hckFKN. (A) Schematic of 
the b-arrestin screen. Upon receptor activation by a ligand, b-arrestin conjugated to b-
galactosidase associates with the receptor, activating the b-galactosidase enzyme. 
Substrate is added, and luminescence measured. (B) Dose-response of hsFKN and 
hckFKN. Both constructs exhibited classical, sigmoidal dose-response curves but 
hsFKN had an approximately 10-fold lower EC50 than hckFKN, indicating greater 
receptor affinity. Data represented as mean ± SEM, obtained from two independent 
experiments performed in quadruplicate. 
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 High Concentrations of FKN Sensitized Microglia to LPS 
 Fractalkine has been shown to signal through its receptor, located on microglia, 
to reduce expression of pro-inflammatory genes such as TNFa (Lyons et al. 2009). We 
conducted an assay using primary rat microglia to investigate the dose-response 
relationship between FKN concentration and its ability to reduce TNFa in LPS-
stimulated microglia. Cells were isolated after enzymatic digestion of neural tissue using 
CD11b/c antibodies coupled to magnetic beads followed by magnetic separation. This 
technique yielded approximately 3 million live cells per rat with a purity of approximately 
80% as measured by flow cytometry (data not shown). Initially we established a dose 
response to LPS stimulation (Fig. 4.2B). This established a dose of LPS, 1 ng/mL, 
where we observed approximately 50% of maximum stimulation, as determined by 
TNFa release. This ensured that we were not overstimulating the microglia and thus not 
obscuring any anti-inflammatory responses to FKN. Furthermore, it allowed us to 
observe if any treatments caused an increase in TNFa release. 
Using two human FKN peptides, we observed a dose-dependent reduction in 
TNFa as the FKN concentration increased from 0.01 nM to 3 nM, with a maximal 
reduction in TNFa of approximately 70% (Fig 4.2C). In agreement with our receptor 
affinity data, the most effective concentration of hsFKN was 1 nM while the protective 
effect of hckFKN plateaued at 3 to 10 nM. This is consistent with the ~10-fold difference 
observed in our EC50 binding data above.  
However, as concentrations of FKN increased, we observed a significant 
rebound in TNFa secretion and, at the highest concentration of hsFKN, we observed an 
exacerbation of TNFa secretion above what LPS alone triggered. A similar response 
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was observed with the ckFKN, but this response appears to be shifted likely due to the 
lower binding affinity. We believe this biphasic response to FKN could be explained by 
1) CX3CR1 internalization (loss of receptor), 2) CX3CR1 signaling through an 
alternative pathway, or 3) FKN is binding and activating a non-canonical receptor at 
high concentrations. Therefore, we examined these possibilities further. 
 
Figure 4.2 High concentrations of FKN increase TNFa secretion. (A) Schematic of 
functional assay. Microglial cells are treated with FKN and then stimulated with LPS. 
Secretion of TNFa is measured by ELISA. (B) Graph of TNFa after stimulation with LPS 
for 4 hours (black line) or 6 hours (grey line). Data represented as mean ± SEM, n=2 (C) 
Graph of TNFa secreted by LPS-stimulated primary microglia after treatment with both 
hsFKN (black line) and hckFKN (grey line). Both hsFKN and hckFKN provide protection 
from LPS stimulation up to approximately 10 nM. However, at higher concentrations 
FKN sensitizes microglia to LPS stimulation and exacerbates TNFa secretion. Data 
represented as mean ± SEM, obtained from three independent experiments performed 
in triplicate. 
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High Concentrations of hsFKN did not cause CX3CR1 Internalization 
To interrogate CX3CR1 localization on primary microglia after exposure to high 
concentrations of FKN, we utilized flow cytometry. Primary microglia were isolated and 
acutely treated with either 1 nM or 100 nM of hsFKN or hckFKN. Analyzing surface 
expression of CX3CR1 on CD11b/c-positive cells, showed a slight reduction (14%) in 
surface receptor staining after incubation with 100 nM hckFKN (Fig. 4.3B & Fig. 4.3D). 
However, there was no significant reduction in surface CX3CR1 staining after treatment 
with 100 nM hsFKN (Fig. 4.3A & Fig. 4.3D). This suggests that receptor internalization 
did not contribute to the loss of anti-inflammatory signaling as determined by TNFa 
release. 
CX3CR1 Antagonism Exacerbated TNFa Secretion in Primary Microglia 
Given the lack of receptor internalization, we next sought to determine if FKN 
might be signaling through a non-canonical receptor to exacerbate TNFa secretion. We 
also wanted to confirm that this effect was not unique to LPS-stimulated cells but could 
apply more broadly. First, we treated primary microglia with 1 nM or 100 nM of FKN 
without stimulating the microglia with LPS (Fig. 4.4A). We observed a dose-dependent 
increase in TNFa secretion that, in cells treated with 100 nM hsFKN, induced 
significantly greater TNFa secretion (~4-fold increase over 1 nM hsFKN) than vehicle 
treated cells (Fig. 4.4A). In order to confirm that BSA, included as a carrier protein with 
the recombinant peptides, was not interfering in our assay, we treated LPS-stimulated 
primary microglia with an equivalent concentration of BSA found in our 100 nM hsFKN 
dilution and observed no change in TNFa secretion (Fig. 4.4D). 
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We then sought to block this effect in LPS-stimulated cells with an antibody 
against CX3CR1. If high concentration FKN was causing aberrant signaling through 
CX3CR1, we hypothesized antagonism of the receptor with an antibody would block this 
effect. As expected, antagonizing CX3CR1 impaired the protective effect of 1 nM sFKN 
but interestingly we observed further increases of TNFa secretion in the 100 nM hsFKN 
group treated with anti-CX3CR1 (Fig. 4.4B). Similar trends were observed with the 
ckFKN (Fig. 4.4C). In the absence of FKN, the addition of anti-CX3CR1 antibody also 
increased TNFa, suggesting that the microglia may produce low levels of endogenous 
FKN in vitro (Fig. 4.4D), which has previously been suggested by Hatori et al. (2002). 
Taken together, these data imply that high concentrations of FKN increase pro-
inflammatory cytokine release and that this may occur via non-canonical signaling 
through another receptor. 
  
 
 
98 
 
Figure 4.3 High concentration hsFKN does not cause receptor internalization. (A) 
Representative trace of hsFKN-treated primary microglia stained for anti-CX3CR1. (B) 
Representative trace of hckFKN-treated primary microglia stained for anti-CX3CR1. (C) 
Graph of mean fluorescence intensity, expressed as percent of vehicle control, of FKN-
treated primary microglia stained for anti-CX3CR1. hsFKN does not dose-dependently 
reduce surface CX3CR1 expression where as 100 nM hckFKN does reduce surface 
CX3CR1 expression compared to 1 nM hckFKN. Data represented as mean ± SEM, 
obtained from two independent experiments. * denotes p<0.05 by Student’s t-test. 
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Figure 4.4 Antagonism of CX3CR1 exacerbated secretion of TNFa by primary 
microglia in the presence of 100 nM FKN. (A) Graph of TNFa secreted in FKN-
treated primary microglia in the absence of LPS. Both hsFKN and hckFKN dose-
dependently increase TNFa secretion in resting microglia. (B) Graph of TNFa secreted 
from LPS-stimulated primary microglia after treatment with high and low concentrations 
of hsFKN in the presence of a-CX3CR1 antibody or IgG control antibody. (C) Graph of 
TNFa secreted from LPS-stimulated primary microglia after treatment with high and low 
concentrations of hckFKN in the presence of anti-CX3CR1 antibody or IgG control 
antibody. Antagonizing CX3CR1 in the presence of 100 nM hsFKN exacerbated TNFa 
secretion. ** denotes p<0.01; *** denotes p<0.001 by Student’s t-test. (D) Graph of 
TNFa secreted from LPS-stimulated primary microglia after treatment with control 
solutions. Incubation with anti-CX3CR1 antibody significantly increased TNFa secretion 
but control IgG and the carrier protein BSA did not. *** denotes p<0.001 by One-Way 
ANOVA and Dunnett’s post-hoc test. Data represented as mean ± SEM, averaged from 
two independent experiments run in triplicate. 
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AAV-mediated Over Expression of ckFKN Exacerbated Learning Deficits
 and Tauopathy in rTg4510 Mice 
We investigated if ckFKN over expression can rescue the rTg4510 mouse model 
of tauopathy. As discussed above, we have previously shown that over expression of 
sFKN is neuroprotective (Nash et al. 2013). Here we observed that ckFKN over 
expression increased locomotor activity in an open field, compared to GFP injected 
controls (Fig. 4.5A). We also observed working memory impairments on the novel 
object recognition task. AAV-ckFKN-injected rTg4510s had significantly less preference 
for the novel object than AAV-GFP-injected rTg4510s or uninjected tTA control mice 
(Fig. 4.5B). In the RAWM task, AAV-ckFKN-injected rTg4510s did not make significantly 
more errors than either GFP-injected rTg4510s or uninjected tTA controls on days 1 and 
2 of the task (Fig. 4.6A & 4.6B), however, ckFKN over expression did significantly 
worsen performance on reversal (Fig. 4.6C & 4.6D). While GFP-injected rTg4510s 
made more errors than uninjected tTA mice, animals over expressing ckFKN made 
significantly more errors than either GFP-injected or the uninjected tTA controls (Fig. 
4.6C & 4.6D). Taken together, these data indicate ckFKN over expression exacerbated 
memory deficits in the rTg4510 tauopathy model. 
We next examined tau hyperphosphorylation in both RIPA-soluble and formic 
acid-soluble hippocampal extracts. We observed over expression of ckFKN significantly 
increased total soluble tau (H150; Fig 4.7A & 4.7B). Furthermore, we observed a trend 
for significantly increased insoluble phospho-tau at serine 396 (Fig 4.7C). Together with 
the worsened performance on reversal, ckFKN over expression negatively impacted the 
phenotype of rTg4510s. 
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Figure 4.5 ckFKN over expression induced hyperlocomotion and impaired 
recognition memory. (A) Graph of distance traveled in an open field. rTg4510s over 
expressing ckFKN traveled significantly further than uninjected tTA controls. (B) Graph 
of percent novel exploration in the novel object recognition task. AAV-ckFKN- injected 
rT4510s had significantly less preference for a novel object compared to both AAV-
GFP- injected rTg4510s or uninjected tTA controls. Data represented as mean ± SEM, 
n=8-16. ** denotes p<0.01; * denotes p<0.05 by Fisher’s LSD. 
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Figure 4.6 ckFKN Over Expression Worsened Cognitive Performance on Reversal. 
(A) Graph of average errors per block made on Day 2 of RAWM. (B) Graph of total 
errors made on Day 1, Day 2, or across both Days 1 & 2 of RAWM. rTg4510s did not 
make significantly more total errors or average errors per block than uninjected tTA 
controls. (C) Graph of average errors per block made on Reversal. (D) Graph of total 
errors made on reversal. AAV-ckFKN- injected rTg4510s made significant more total 
errors on reversal than either AAV-GFP- injected rTg4510s or uninjected tTA control 
mice. Both AAV-ckFKN- and AAV-GFP- injected rTg4510s made significantly more total 
errors on reversal than uninjected tTA controls and AAV-ckFKN- injected rTg4510s 
made significantly more errors than AAV-GFP- injected rTg4510s. Data represented as 
mean ± SEM, n=8-16. ** denotes p<0.01; * denotes p<0.05 by Fisher’s LSD 
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Figure 4.7 ckFKN Over Expression Increased Soluble Tau in rTg4510s. (A) Graph 
of soluble total tau (H150) and tau phosphorylated at Serine 199/202 (pS199/202) or 
Serine 396 (pS396) analyzed by Western blot. rTg4510s over expressing ckFKN had 
significantly elevated RIPA-soluble total tau (H150) but no significant alterations in 
soluble phospho-tau. (B) Representative blots for each marker. (C) Graph of formic acid 
soluble total tau (H150) and tau phosphorylated at Serine 396 (pS396). There was a 
trend for increased insoluble pS396 tau in animals over expressing ckFKN, but it did not 
reach significance. Intensity of blots from all animals were averaged and converted to 
fold change for display. Data represented as mean ± SEM, n=8-12. * denotes p<0.05 by 
two-tailed Student’s t-test.  
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Discussion 
 Recently, studies have reported conflicting results regarding which variant of 
FKN, membrane bound or soluble, is neuroprotective. Two studies in different 
Parkinson’s disease models have shown that soluble FKN, which includes the mucin-
like stalk, is neuroprotective (Morganti et al. 2012; Nash et al. 2015). However, results 
have been mixed in models of Alzheimer’s disease. Over expression of sFKN has been 
shown to be neuroprotective in a tauopathy model, whereas obligate-expression of 
ckFKN was not protective in either an amyloid-depositing or a tau expressing model 
(Bemiller et al. 2018; Lee et al. 2014; Nash et al. 2013). As discussed above, ckFKN but 
not sFKN has been shown to significantly increase mechanical allodynia (Clark and 
Malcangio 2012). These data support the notion that sFKN and ckFKN may activate 
CX3CR1 in unique ways. 
Here, we report that sFKN had stronger affinity for CX3CR1 than the ckFKN 
peptide (EC50 0.38 nM vs 4.2 nM, respectively). This is consistent with calcium imaging 
data where the sFKN was shown to generate significantly greater responses at the 
same dose as ckFKN (Clark and Malcangio 2012). While the ckFKN peptide ligated 
CX3CR1, it did so with approximately 10-fold lower affinity than sFKN. This suggests 
that the mucin-like stalk may play a role in receptor binding. The necessity of the mucin-
like stalk for binding of membrane-bound FKN to CX3CR1 has been previously reported 
but the involvement of the mucin-like stalk in soluble FKN signaling has not been 
investigated (Ostuni et al. 2014). We propose that in soluble FKN signaling, the mucin-
like stalk may act as an allosteric modulator, increasing receptor affinity and thus 
activation. Alternatively, the stalk may be important for chemokine structure, allowing 
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the chemokine to adopt a more favorable conformation with greater affinity for CX3CR1. 
Finally, the mucin-like stalk may also bind to other cell surface proteins which either 
enhances or stabilizes the chemokine domain to CX3CR1. 
In order to assess the differential effects of FKN signaling in a functional assay, 
primary microglia were isolated from adult rat brains. It is well established that FKN 
reduces proinflammatory responses in microglial cells, including reductions in TNFa and 
IL-1b, which are cytokines that have been implicated in neurodegenerative diseases 
such as AD (Patel et al. 2005; Tarkowski et al. 2003). Therefore, we challenged 
microglia with lipopolysaccharide (LPS), stimulating secretion of the pro-inflammatory 
cytokine TNFa, and then examined changes in the TNFa response after sFKN and 
ckFKN agonism. As previously reported, we observed that FKN reduced TNFa 
secretion in a dose-dependent manner (Fig. 4.2c) (Zujovic et al. 2000). CX3CR1 
agonism with either of the soluble FKN fragments reduced TNFa secretion by 
approximately 70%. However, reflecting the ~10-fold difference in receptor affinity, the 
most effective concentrations of sFKN and ckFKN were ~1 and ~10 nM, respectively. 
Intriguingly, the reduction in TNFa was not observed at higher concentrations of 
FKN. Increasing FKN concentrations to 100 nM caused a loss of anti-inflammatory 
activity and thus no reduction in TNFa secretion. Surprisingly, 100 nM sFKN 
significantly increased TNFa secretion over the levels observed for LPS controls. We 
saw a similar response with ckFKN, however, due to the lower affinity we did not 
increase the TNFa above the LPS control but would predict that higher concentrations 
would continue to increase the TNFa as observed with sFKN. This suggests that FKN 
can lose its anti-inflammatory effects at high concentrations, regardless of which soluble 
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species is being expressed. To determine if FKN can stimulate TNFa secretion at high 
concentrations in LPS-naïve microglia, we treated primary microglia with 1 nM or 
100 nM FKN in the absence of LPS. Again, we observed a dose-dependent increase in 
TNFa secretion. Consistent with our data in LPS-stimulated cells, 100 nM hsFKN 
increased TNFa secretion above vehicle-treated levels where as 100 nM hckFKN did 
not. These differences between the soluble FKN variants may be explained by receptor 
affinity. These data highlight potential confounds in studies using FKN ligands and the 
concentration at which they are used. The lack of anti-inflammatory action of high 
concentrations of FKN may explain the lack of neuroprotective effect of FKN in models 
of stroke as well as in the APP/PS1;SolTg mice, which had approximately 60-fold over 
expression of ckFKN. 
Initially, we believed the biphasic response to increasing concentrations of FKN 
was likely due to receptor internalization and thus loss of signaling at the high doses. 
Hjorto et al. (2009) have demonstrated internalization of labeled soluble FKN, which 
would suggest receptor internalization with ligand binding. Therefore, we investigated 
the level of cell surface receptors after treatment with a low (1 nM) and a high (100 nM) 
dose of FKN using flow cytometry. As seen in Figure 4.3, we observed a slight, but 
significant, reduction in the amount of surface CX3CR1 on primary microglia treated 
with 100 nM hckFKN but not 100 nM hsFKN. The hckFKN results may reflect those 
reported in mice expressing only murine ckFKN where they observed a reduction in 
microglial surface CX3CR1 (Bemiller et al. 2018), however our reduction was not as 
dramatic (20% verses a 50% reduction). This might be due to differences in the 
environment (in vitro vs in vivo) or due to the level of brain ckFKN present in the mouse. 
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A previous report in a mouse over expressing ckFKN by approximately 60-fold showed 
no internalization of the receptor by flow cytometry (Lee et al. 2014). The lack of 
CX3CR1 loss in the sFKN group would argue that receptor internalization is not the 
driving force behind the upturn in TNFa expression at the high FKN concentration and 
suggests that an alternative mechanism is contributing to the response. 
To investigate whether FKN at high concentrations is signaling through a non-
canonical pathway, an anti-CX3CR1 antibody was used to antagonize the receptor. As 
expected at 1 nM hsFKN, CX3CR1 antagonism blocked the anti-inflammatory response 
to FKN, demonstrating FKN signaling through CX3CR1. At 100 nM hsFKN with the 
control IgG, we again observed an increase in TNFa over LPS alone, however, with the 
anti-CX3CR1 antibody we observed a further exacerbation of TNFa secretion (Fig. 
4.4B). We observed similar results with the hckFKN although somewhat blunted in 
overall response as expected.  This data would suggest that the increase in TNFa at 
high FKN concentrations is not through an alternative activation pathway for CX3CR1 
because CX3CR1 activation was blocked with the anti-CX3CR1 antibody.  Furthermore, 
we believe these results suggest that we are observing two opposing actions of FKN at 
the higher concentration. An anti-inflammatory signaling through CX3CR1 (which was 
blocked with the antibody) and a second signaling event that is proinflammatory. As this 
activation of TNFa is independent of CX3CR1 signaling, it would also suggest that the 
proinflammatory signaling is through an as yet unknown receptor.  
Previous reports have identified a potential interaction between FKN and the 
integrin receptors a4b1, a5b1, and a5b3 (Fujita et al. 2012; Fujita et al. 2014). Fujita et al. 
(2014) reported that FKN can activate the a5b1 integrin receptor independently of 
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CX3CR1 binding, in concentrations ranging from 8-80 nM. This integrin has been shown 
previously to bind recombinant neurotoxic prion protein, inducing expression of pro-
inflammatory genes in the microglial cell line BV2 (Chang et al. 2012). Furthermore, a-
synuclein oligomers can bind a5b1, inducing microglial migration, indicating that a5b1 
receptor agonism may be pro-inflammatory (Kim et al. 2014). Therefore, the pro-
inflammatory action of FKN we observed at 100 nM may be due to an interaction with 
the a5b1 integrin receptor. Further work is needed to determine if this is the case. 
We have previously reported sFKN over expression to be neuroprotective in the 
rTg4510 mouse model of tauopathy (Nash et al. 2013). In order to investigate the 
effects of ckFKN over expression on tauopathy, we injected rTg4510s with AAV over 
expressing ckFKN. We observed that ckFKN over expression significantly impaired 
reversal learning on the radial arm water maze task. Furthermore, over expression of 
ckFKN significantly increased soluble total tau and there was a trend for a significant 
increase in insoluble pSer396 phospho-tau. These findings are in agreement with the 
recent report by Bemiller et al. (2018) in which ckFKN expression did not rescue 
cognitive deficits or tau hyperphosphorylation induced by loss of Cx3cl1 in the hTau 
model of tauopathy. The authors also observed an increase in microglial activation and 
a reduction in surface expression of CX3CR1 in animals expressing only ckFKN 
compared to Cx3cl1-/- and nontransgenic mice. 
Our data demonstrates that although both sFKN and ckFKN signal through the 
CX3CR1 receptor, there are clear differences in receptor affinity, which can affect 
microglial responses in a dose dependent manner. Furthermore, our data demonstrate 
that high FKN concentrations, of either ligand, does not confer protection against pro-
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inflammatory stimuli such as LPS and can even exacerbate the proinflammatory 
response at the highest concentration tested. This loss of protection is not due to 
receptor internalization with the sFKN ligand but appears to be mediated through an 
alternative receptor interaction. These data suggest that there may be a delicate 
balance between proinflammatory inhibition by FKN and proinflammatory activation by 
FKN. Therefore, care needs to be taken in studies that will examine FKN. It is currently 
unknown if high concentrations of soluble FKN are achievable in the CNS but 
concentrations as low as 30 nM would have a significantly negative effect on FKN’s 
anti-inflammatory action. It may be possible in areas of cell damage that a localized 
increase in soluble FKN may reach these levels and have a negative impact on 
microglial activation. This may explain why in MCAO studies FKN has been shown to 
negatively impact lesion size (Chapman et al. 2000; Cipriani et al. 2011; Dénes et al. 
2008; Soriano et al. 2002). The proinflammatory response at high concentrations may 
also explain the disparate results for neuroprotection in AD animal models. Alternatively, 
these conflicting studies may simply reflect the lower binding affinity of ckFKN and thus 
a reduced anti-inflammatory response. We believe that our data highlight the need for 
more research to explicitly determine the microglial phenotype resulting from FKN 
signaling at low nanomolar concentrations which would be indicative of a more 
neuroprotective microglial phenotype. Research into determining the alternative 
activation pathway with FKN at high concentrations may also yield novel therapeutic 
interventions for chronic pain and stroke. 
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CHAPTER FIVE: 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
The potential for inflammation to play a role in AD was noted in findings of 
epidemiological studies that showed long-term, high-dose non-steroidal anti-
inflammatory drug (NSAID) use reduced the risk for AD (McGeer et al. 2006). However, 
clinical trials have failed to show significant protective or treatment effects of NSAID 
administration (reviewed in (Heneka et al. 2015)). Therefore, attention has shifted to 
immunomodulation rather than suppression of inflammation as an avenue of 
investigation. Immunomodulators, such as FKN, can reduce pro-inflammatory activation 
of microglia, which may in turn prevent microglial dystrophy due to prolonged exposure 
to pro-inflammatory cytokines. This may allow microglia to prevent, rather than promote, 
neurodegeneration. 
 Fractalkine (FKN) is unique among chemokines, being the only member of the 
CX3C motif family and sharing a one-to-one relationship with its receptor. FKN is a 
transmembrane protein with an N-terminal chemokine domain followed by a long, 
mucin-like stalk attached to a short transmembrane domain and C-terminal intracellular 
domain. FKN is capable of signaling as either a membrane bound protein, or it can be 
cleaved by several proteases, such as a disintegrin and metalloprotease (ADAM) 10, 
ADAM 17, and cathepsin S (Clark et al. 2009; Garton et al. 2001; Hundhausen et al. 
2003). Cleavage of FKN by ADAM 10 or ADAM 17 generates a soluble fragment that 
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includes the entire ectodomain of FKN whereas cleavage by cathepsin S is thought to 
generate a smaller fragment (Fonovic et al. 2013; Jones et al. 2013). FKN signaling has 
been implicated in neurodegeneration, both as neuroprotective and neurotoxic 
(Cardona et al. 2006; Cipriani et al. 2011; Fumagalli et al. 2013; Nash et al. 2013). It 
may be the context of FKN signaling, as well as which soluble species is generated, that 
determines the effects of FKN signaling. 
 Herein, we demonstrated that over expression of the putative ADAM10/17 
cleavage variant of FKN (sFKN) can improve learning and memory in the rTg4510 
mouse model of tauopathy. Importantly, we showed that sFKN is capable of 
ameliorating cognitive deficits even when administered after the onset of both cognitive 
impairment and deposition of insoluble tau. This was achieved by utilizing the unique 
properties of adeno-associated virus (AAV) serotype 4 to infect ependymal cells, which 
increased sFKN levels in the cerebrospinal fluid and parenchyma. We observed a 
significant improvement of recognition memory and spatial memory in AAV-sFKN-
injected animals compared to AAV-GFP-injected rTg4510s. This could significantly 
impact AD and other neurodegenerative diseases. Prior work suppressing P301L tau 
expression in this model demonstrated that memory deficits can be rescued without 
significant impact on tauopathy. This implies that, early in the disease process, memory 
may be improved without significantly impacting tauopathy. These memory 
improvements could have a profound impact on the quality of life of dementia patients. 
Indeed, a five-year delay of the need for extensive or residential care for AD patients 
could lead to a 40% reduction in costs by 2050 (Zissimopoulos et al. 2014). 
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Although we observed an improvement in cognition, we did not observe a 
significant reduction in hyperphosphorylated tau. This may be due to the advanced age 
at which we injected the mice. In the rTg4510 model, suppressing transgene expression 
in mice after 4.5 months of age fails to reduce hyperphosphorylated tau, indicating that 
pathology is transgene independent at this stage (Santacruz et al. 2005; Spires et al. 
2006). We hypothesize that sFKN over expression altered the inflammatory milieu, 
creating a more permissive environment for learning and memory. Unfortunately, we 
were unable to adequately assess the microglial phenotype with the limited number of 
markers in our multiplex ELISA array. Current ongoing experiments are using RNA 
sequencing to examine how increased FKN signaling in this model alters the microglial 
phenotype. Since there are no published agonist compounds for CX3CR1, identification 
of how FKN alters the microglial phenotype may offer novel druggable pathways that 
could alter microglial activation to achieve the same phenotype as FKN agonism. This 
could have significant impact in AD and other neurodegenerative disease in which 
neuroinflammation plays a significant role. 
In our second study, we sought to eliminate some of the pathology-independent 
effects in the rTg4510 mouse model, such as neurodegeneration in the CA1 and 
dentate gyrus as well as impaired spatial navigation prior to the appearance of tau 
tangles, by suppressing transgene expression from conception to 3 weeks of age 
(Ramsden et al. 2005; Spires et al. 2006). Mice were injected at either two months of 
age, prior to the onset of insoluble tau deposition, or five months of age, after the onset 
of insoluble tau deposition. These two cohorts were assessed at six and eight months of 
age, respectively. Surprisingly, suppression of transgene expression during 
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development had an outsized impact on the cognitive performance of these mice. We, 
and others, have previously reported that this model develops cognitive deficits as early 
as 2.5 months of age and reliability exhibits cognitive deficits and hyperactivity by 5 
months of age (Brownlow et al. 2013; Brownlow et al. 2014; Joly-Amado et al. 2016; 
Nash et al. 2013; Santacruz et al. 2005). However, at both six and eight months of age, 
the animals that had received doxycycline from conception to weaning did not display 
typical rTg4510 deficits. Mice lacked the hyperactive phenotype and the cognitive 
impairment observed in radial arm water maze was absent in the preventative study and 
comparatively mild in the therapeutic study. Although this is a very informative finding 
for the field and may allow the study of pathology in aged animals without extended 
doxycycline treatment, it unfortunately negatively impacted our ability to assess rescue 
of behavioral outcome measures in this study. 
Although cognitive deficits were significantly delayed by doxycycline treatment, 
we were able to assess tau pathology. We found sFKN had a positive impact on 
pathology whether administered in either the preventative paradigm or the therapeutic 
paradigm (after pathology has developed). In the preventative study AAV-sFKN-injected 
rTg4510 mice had significantly less phospho-serine 396 tau in both the soluble and 
insoluble fraction as compared to AAV-GFP-injected rTg4510s. In the therapeutic study 
design, AAV-sFKN-injected rTg4510s in the older cohort of mice had a strong trend for 
reduced soluble pSer396 tau compared to AAV-GFP-injected rTg4510s. In both cohorts 
of mice, sFKN significantly reduced insoluble pSer396 tau. Phosphorylation of tau at 
serine 396 is a paired helical filament-associated phosphorylation event, detectable only 
in late-stage AD (Neddens et al. 2018). By reducing this species of phospho-tau, sFKN 
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over expression may have reduced conversion of soluble tau into neurotoxic oligomers, 
PHFs, and neurofibrillary tangles. 
In both of our studies over expressing sFKN in the brain, we observed an 
increase in expression of vascular endothelial growth factor (VEGF). While VEGF is 
most known as a vascular growth factor, it has been recently shown to have direct 
effects on neurons. VEGF has been shown to protect primary hippocampal neurons 
from excitotoxicity in vitro and promote neurogenesis in vivo (Jin et al. 2002; Matsuzaki 
et al. 2001). In a model of Alzheimer’s disease, VEGF over expression improved 
cognitive functioning in CRND8 mice (Religa et al. 2013). The finding of increased 
VEGF signaling, both at the transcript and protein level, in this dissertation point to a 
potential mechanism of action of sFKN responsible for mediating cognitive 
improvements and ameliorating tauopathy. 
Although we have shown sFKN over expression to be beneficial, there is 
controversy in the literature regarding which CX3CR1 ligand, membrane-bound or a 
proteolytically cleaved soluble species, confers neuroprotection. In neuropathic pain, the 
functional involvement of FKN signaling has been shown to be dependent on protease 
cleavage of membrane-bound FKN, and thus the soluble species released. It was 
reported that cathepsin S can cleave FKN and that this cleavage product was 
necessary for the development of mechanical allodynia in a spinal injury model (Clark et 
al. 2007; Clark et al. 2009). Furthermore, intrathecal infusion of the chemokine domain 
of FKN (ckFKN) caused mechanical allodynia in non-lesioned rats while intrathecal 
infusion of sFKN did not (Clark and Malcangio 2012). Suggesting that careful attention 
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must be paid to the ligand used in over expression or exogenous application studies as 
they may have different biological activities. 
Reports in AD mouse models have further confounded the debate. Previous 
reports indicated that loss of FKN signaling is beneficial in models of amyloid deposition 
but detrimental in models of tauopathy (Bhaskar et al. 2010; Lee et al. 2010b). In order 
to determine if these opposing effects were due to loss of membrane-bound FKN or 
soluble FKN signaling, Lee et al. (2014) generated an APP/PS1 mouse that over 
expressed ckFKN but lacked endogenous, membrane-bound FKN (referred to as 
APP/PS1;SolTg). The ckFKN construct was shown to have biological activity in vivo by 
rescuing transepithelial dendrite formation by intestinal macrophages (Kim et al. 2011). 
However, Lee et al. (2014) observed that ckFKN did not rescue the phospho-tau 
pathology in the APP/PS1;Cx3cl-/- mice. Similarly, Bemiller et al. (2018) investigated 
ckFKN signaling in the hTau model of tauopathy. The authors observed that mice 
expressing only ckFKN were equally sensitive to LPS-induced tau 
hyperphosphorylation, cognitive impairments and microglial activation as Cx3cl1-/- 
mice. Furthermore, hTau mice expressing only ckFKN had tau pathology, cognitive 
impairments, and associated microglial activation similar to those observed in 
hTau;Cx3cl1-/- mice (Bemiller et al. 2018). These data are contrary to previous work 
and the results of this dissertation, which show that sFKN overexpression is capable of 
reducing tauopathy and neurodegeneration in rTg4510 mice (Nash et al. 2013). One 
obvious difference between these studies is the soluble FKN that was used, ckFKN 
(only the chemokine domain) versus sFKN (chemokine domain with the mucin-like 
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stalk). This led us to investigate any differences in signaling between these two soluble 
fragments of FKN and if this may explain the contradicting results. 
We demonstrate that both sFKN and ckFKN are capable of binding and signaling 
through CX3CR1, however ckFKN has reduced binding efficacy. Utilizing a beta-arrestin 
reporter, we observed that the EC50 for sFKN was approximately 10-fold less than 
ckFKN (0.38 nM and 4.2 nM, respectively). This reduced binding was also reflected in 
its anti-inflammatory activity where we observed sFKN more potently reduced secretion 
of TNFa in LPS-stimulated microglial cells. The most interesting finding here maybe the 
bimodal response we observed with increasing FKN concentrations. We observe that  
excessive concentrations of FKN does not confer an anti-inflammatory response and 
can even exacerbate TNFa secretion by microglia with or without LPS stimulation. This 
effect cannot be accounted for by reduced surface expression of CX3CR1 at high 
concentrations of sFKN. When an anti-CX3CR1 antibody is included in the treatment, 
the protective effects of low-concentrations of FKN were blocked while the TNFa 
release at high-concentrations of FKN is further exacerbated. This suggests FKN is 
signaling through a non-canonical pathway at high concentrations, causing an increase 
in microglial activation. 
Previous reports have identified several integrin receptors with which FKN is 
capable of interacting (Fujita et al. 2012; Fujita et al. 2014). One of these integrin 
receptors is responsible for up-regulation of pro-inflammatory transcripts in microglia 
exposed to the prion protein (Chang et al. 2012). We hypothesize that high 
concentrations of FKN are binding this integrin receptor, causing the loss of anti-
inflammatory phenotype we observed. FKN would not be the first chemokine to be 
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shown to have a bimodal response. CXCL1 and CXCL7 have been shown to induce 
biphasic responses in polymorphonuclear neutrophil granulocytes over four orders of 
magnitude extending into the micromolar concentration range. At low concentrations, 
signaling occurred through CXCR-2 whereas at high concentrations signaling occurred 
through CXCR-1 and was due to CXCR-2 internalization (Ludwig et al. 1997). Similarly, 
MCP-1 may selectively cause chemotaxis of specific immune cell-types dependent on 
the concentration of MCP-1 (Heinemann et al. 2000). Further characterization of the 
concentration-dependent signaling of FKN is needed to determine the biological 
significance of this phenomenon. 
Interestingly, activation of integrins by FKN may also partially explain the 
beneficial cognitive effects observed in the first study. Integrin activation has been 
shown to play a role in learning and memory in rodents. Specifically, b1 integrins have 
been shown to be necessary for normal synaptic functioning. Knocking out b1 integrins 
impairs basal, AMPA receptor synaptic transmission, reduces NMDA-dependent LTP, 
and impairs working memory (Chan et al. 2006). Furthermore, disrupting b1 integrin 
signaling after theta-burst stimulation impairs LTP consolidation (Babayan et al. 2012). 
These data imply that activating b1 integrins could improve cognitive functioning. 
Our identification of differences in activity with sFKN and ckFKN may explain why 
there are conflicting reports in the literature. In the report by Lee et al. (2014), the 
authors observed an approximately 60-fold over expression of ckFKN in the 
APP/PS1;SolTg mouse compared to APP/PS1 mice. This level of expression may yield 
concentrations of ligand that could lead to reduction or ablation of the anti-inflammatory 
effects of FKN in vivo. Thus, in the APP/PS1;SolTg mice there could be a similar 
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biological outcome to APP/PS1,CX3CL1-/- mice: an increase in the pro-inflammatory 
activation of microglia and concomitant reductions in amyloid and increases in tau 
pathology. Loss of anti-inflammatory signaling at high concentrations of FKN may also 
explain results in models of stroke. It has been observed that FKN negatively impacts 
lesion size in MCAO studies (Cipriani et al. 2011; Dénes et al. 2008; Fumagalli et al. 
2013; Soriano et al. 2002). Chapman et al. (2000) observed that cleavage of FKN from 
neuronal membranes occurs acutely after excitotoxic injury and precedes neuronal loss. 
It is possible that, in areas of neuronal damage, local concentrations of FKN increase 
beyond those with anti-inflammatory effects. Further work investigating the 
concentration of FKN released during acute neuronal injury and neurodegeneration is 
needed to determine if this is the case. 
This body of work suggests that increased FKN expression is neuroprotective in 
tauopathy. Over expression of the ADAM10/17 cleavage variant reduced tau 
hyperphosphorylation and improved cognitive performance even when administered 
after the onset of tau deposition and cognitive deficits. Furthermore, sFKN over 
expression slowed the accumulation of hyperphosphorylated tau when administered 
prior to the onset of tau deposition. However, we demonstrate that the choice of ligand 
is important. We have shown subtle differences in receptor affinity and signaling 
between the sFKN and ckFKN cleavage variants. Furthermore, at high concentrations 
FKN may be signaling through non-canonical pathways, resulting in pro-inflammatory 
activation of microglia. More work is needed to identify the potential pathway(s) through 
which FKN exerts its effects and the resulting microglial phenotype.  
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